JP2011506271A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506271A5 JP2011506271A5 JP2010530598A JP2010530598A JP2011506271A5 JP 2011506271 A5 JP2011506271 A5 JP 2011506271A5 JP 2010530598 A JP2010530598 A JP 2010530598A JP 2010530598 A JP2010530598 A JP 2010530598A JP 2011506271 A5 JP2011506271 A5 JP 2011506271A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- nozzle
- particles
- droplets
- microparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims description 113
- 239000002245 particle Substances 0.000 claims description 81
- 239000011859 microparticle Substances 0.000 claims description 76
- 239000000839 emulsion Substances 0.000 claims description 73
- 239000012530 fluid Substances 0.000 claims description 57
- 239000003795 chemical substances by application Substances 0.000 claims description 53
- 230000000975 bioactive Effects 0.000 claims description 47
- 239000000017 hydrogel Substances 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 239000002904 solvent Substances 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 8
- 210000004080 Milk Anatomy 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 238000009738 saturating Methods 0.000 claims description 2
- -1 poly (1,4-butylene) terephthalate Polymers 0.000 description 51
- 239000003814 drug Substances 0.000 description 41
- 229940079593 drugs Drugs 0.000 description 38
- 239000000243 solution Substances 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 229920001707 polybutylene terephthalate Polymers 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 238000009826 distribution Methods 0.000 description 18
- 229920001577 copolymer Polymers 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 238000007641 inkjet printing Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 14
- 230000002209 hydrophobic Effects 0.000 description 14
- 229920002451 polyvinyl alcohol Polymers 0.000 description 12
- 238000006065 biodegradation reaction Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000004372 Polyvinyl alcohol Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000654 additive Substances 0.000 description 7
- 239000010419 fine particle Substances 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 201000006353 filariasis Diseases 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000002872 contrast media Substances 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 201000004792 malaria Diseases 0.000 description 5
- 229920001515 polyalkylene glycol Polymers 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 210000001736 Capillaries Anatomy 0.000 description 4
- 229940088597 Hormone Drugs 0.000 description 4
- 210000004940 Nucleus Anatomy 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000000844 anti-bacterial Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007172 antigens Proteins 0.000 description 4
- 102000038129 antigens Human genes 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 229920000249 biocompatible polymer Polymers 0.000 description 4
- 229920002988 biodegradable polymer Polymers 0.000 description 4
- 239000004621 biodegradable polymer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000000670 limiting Effects 0.000 description 4
- 238000011068 load Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 230000002459 sustained Effects 0.000 description 4
- 229940061720 Alpha Hydroxy Acids Drugs 0.000 description 3
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- 108060003951 Immunoglobulins Proteins 0.000 description 3
- 102000018358 Immunoglobulins Human genes 0.000 description 3
- 241000222722 Leishmania <genus> Species 0.000 description 3
- JQXXHWHPUNPDRT-ZNQWNCHJSA-N O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)Nc2c(O)c3c(O)c4C)C)OC)c4c1c3c(O)c2C=NN1CCN(C)CC1 Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)Nc2c(O)c3c(O)c4C)C)OC)c4c1c3c(O)c2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-ZNQWNCHJSA-N 0.000 description 3
- 241000223960 Plasmodium falciparum Species 0.000 description 3
- 229920002732 Polyanhydride Polymers 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 229920001710 Polyorthoester Polymers 0.000 description 3
- 229940081190 Rifampin Drugs 0.000 description 3
- 210000001685 Thyroid Gland Anatomy 0.000 description 3
- 241000223104 Trypanosoma Species 0.000 description 3
- 230000000111 anti-oxidant Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000003115 biocidal Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000004305 biphenyl Chemical group 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 230000001419 dependent Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 102000034387 fluorescent proteins Human genes 0.000 description 3
- 108091006031 fluorescent proteins Proteins 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 244000045947 parasites Species 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 229960001225 rifampicin Drugs 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 201000004409 schistosomiasis Diseases 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 229960005404 sulfamethoxazole Drugs 0.000 description 3
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 3
- 239000007762 w/o emulsion Substances 0.000 description 3
- VQOXZBDYSJBXMA-NQTDYLQESA-N (1S,3R,4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,25R,27R,29R,32R,33R,35S,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14, Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 229960003805 Amantadine Drugs 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 229960003071 Bacitracin Drugs 0.000 description 2
- 229960003677 Chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N Chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N Codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 2
- 229960001334 Corticosteroids Drugs 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960000684 Cytarabine Drugs 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 108010051088 Delta Sleep-Inducing Peptide Proteins 0.000 description 2
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Di(p-aminophenyl)sulphone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 229940114721 Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Drugs 0.000 description 2
- ONKUMRGIYFNPJW-KIEAKMPYSA-N Etynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 2
- 102100009906 F7 Human genes 0.000 description 2
- 108010023321 Factor VII Proteins 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N Gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 2
- 229960000282 Metronidazole Drugs 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 229920000471 Poly(ethylene oxide)-block-polylactide Polymers 0.000 description 2
- WKSAUQYGYAYLPV-UHFFFAOYSA-N Pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 241000242680 Schistosoma mansoni Species 0.000 description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfizole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229960002180 Tetracycline Drugs 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 229960001196 Thiotepa Drugs 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- 229960001082 Trimethoprim Drugs 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N Trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 229960003942 amphotericin B Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory Effects 0.000 description 2
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N dilactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229960000218 etynodiol Drugs 0.000 description 2
- 229940012413 factor VII Drugs 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229960001910 lynestrenol Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- WJEONXLNSWFNNV-UHFFFAOYSA-N octan-2-yl 2,3,5-triiodobenzoate Chemical compound CCCCCCC(C)OC(=O)C1=CC(I)=CC(I)=C1I WJEONXLNSWFNNV-UHFFFAOYSA-N 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 2
- 229940065514 poly(lactide) Drugs 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229960000611 pyrimethamine Drugs 0.000 description 2
- 230000000087 stabilizing Effects 0.000 description 2
- 229960000654 sulfafurazole Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002522 swelling Effects 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- ZRZROXNBKJAOKB-GFVHOAGBSA-N (2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]pentanedioic acid Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 ZRZROXNBKJAOKB-GFVHOAGBSA-N 0.000 description 1
- YPBATNHYBCGSSN-DSZSVDOYSA-N (2S,5R,6R)-3,3-dimethyl-6-[[2-[(3-methylsulfonyl-2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C=1C=CC=CC=1)NC(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-DSZSVDOYSA-N 0.000 description 1
- LQQIVYSCPWCSSD-HSZRJFAPSA-N (3S)-3-(1-benzylpiperidin-4-yl)-3-phenylpiperidine-2,6-dione Chemical compound O=C1NC(=O)CC[C@@]1(C=1C=CC=CC=1)C1CCN(CC=2C=CC=CC=2)CC1 LQQIVYSCPWCSSD-HSZRJFAPSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- DHPRQBPJLMKORJ-XRNKAMNCSA-N (4S,4aS,5aS,6S,12aR)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O DHPRQBPJLMKORJ-XRNKAMNCSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 description 1
- MEZCUMCMVYZPAH-HVIRSNARSA-N (6S,8S,9S,10R,11S,13S,14S,17R)-6-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MEZCUMCMVYZPAH-HVIRSNARSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- POILWHVDKZOXJZ-ARJAWSKDSA-M (Z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OMIVCRYZSXDGAB-UHFFFAOYSA-N 1,4-butanediyl Chemical group [CH2]CC[CH2] OMIVCRYZSXDGAB-UHFFFAOYSA-N 0.000 description 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- OZOMQRBLCMDCEG-VIZOYTHASA-N 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-VIZOYTHASA-N 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N 1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-Deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-Furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-JMRHEKERSA-N 2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acet Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)OC1C(C(C(OC2OC(C)C(O)C(C)(O)C2)C(C)O1)N(C)C)O)OC)C1CCC(N(C)C)C(C)O1 ACTOXUHEUCPTEW-JMRHEKERSA-N 0.000 description 1
- ZRZROXNBKJAOKB-UHFFFAOYSA-N 2-[[2-[[2-[2-[[2-[[2-[[2-[2-[[2-amino-3-(1H-indol-3-yl)propanoyl]amino]propanoylamino]acetyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]propanoylamino]-3-hydroxypropanoyl]amino]acetyl]amino]pentanedioic acid Chemical compound C1=CC=C2C(CC(N)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)NC(CC(O)=O)C(=O)NC(C)C(=O)NC(CO)C(=O)NCC(=O)NC(CCC(O)=O)C(O)=O)=CNC2=C1 ZRZROXNBKJAOKB-UHFFFAOYSA-N 0.000 description 1
- NYEZZYQZRQDLEH-UHFFFAOYSA-N 2-ethyl-4,5-dihydro-1,3-oxazole Chemical compound CCC1=NCCO1 NYEZZYQZRQDLEH-UHFFFAOYSA-N 0.000 description 1
- WSQZNZLOZXSBHA-UHFFFAOYSA-N 3,8-dioxabicyclo[8.2.2]tetradeca-1(12),10,13-triene-2,9-dione Chemical compound O=C1OCCCCOC(=O)C2=CC=C1C=C2 WSQZNZLOZXSBHA-UHFFFAOYSA-N 0.000 description 1
- ZVSXNPBSZYQDKJ-UHFFFAOYSA-N 3,8-dioxabicyclo[8.3.1]tetradeca-1(14),10,12-triene-2,9-dione Chemical compound O=C1OCCCCOC(=O)C2=CC=CC1=C2 ZVSXNPBSZYQDKJ-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N 3-hydroxy-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-Aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- SFHBJXIEBWOOFA-UHFFFAOYSA-N 5-methyl-3,6-dioxabicyclo[6.2.2]dodeca-1(10),8,11-triene-2,7-dione Chemical compound O=C1OC(C)COC(=O)C2=CC=C1C=C2 SFHBJXIEBWOOFA-UHFFFAOYSA-N 0.000 description 1
- HLFSDGLLUJUHTE-UHFFFAOYSA-N 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole Chemical compound N1=C2SCCN2CC1C1=CC=CC=C1 HLFSDGLLUJUHTE-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N 6-propyl-2-thio-Uracil Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229940035620 ACTH and synthetic analog preparations Drugs 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 102100018024 ANG Human genes 0.000 description 1
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 231100000764 Actin inhibitor Toxicity 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N Actinospectacin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229940023040 Acyclovir Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N Alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 229960001391 Alfentanil Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N Allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960002692 Allylestrenol Drugs 0.000 description 1
- ATXHVCQZZJYMCF-XUDSTZEESA-N Allylestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)CC=C)[C@@H]4[C@@H]3CCC2=C1 ATXHVCQZZJYMCF-XUDSTZEESA-N 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960001220 Amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229940046836 Anti-estrogens Drugs 0.000 description 1
- 229960005348 Antithrombin III Drugs 0.000 description 1
- 102000004411 Antithrombin-III Human genes 0.000 description 1
- 108090000935 Antithrombin-III Proteins 0.000 description 1
- 108090000111 Antitoxins Proteins 0.000 description 1
- 229960004046 Apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N Apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 101800001866 Atrial natriuretic peptide Proteins 0.000 description 1
- 229960000794 Baclofen Drugs 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940092705 Beclomethasone Drugs 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N Benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 1
- AVWWVJUMXRXPNF-UHFFFAOYSA-N Bephenium hydroxynaphthoate Chemical compound C=1C=CC=CC=1C[N+](C)(C)CCOC1=CC=CC=C1 AVWWVJUMXRXPNF-UHFFFAOYSA-N 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N Biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 229940052491 Bordetella pertussis Drugs 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 108010076776 Botulinum Antitoxin Proteins 0.000 description 1
- 229960002802 Bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N Bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N Bupivacaine Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- 229960004205 CARBIDOPA Drugs 0.000 description 1
- 102100013472 CCK Human genes 0.000 description 1
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N CHEMBL530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 description 1
- 229960004015 Calcitonin Drugs 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- RCKMWOKWVGPNJF-UHFFFAOYSA-N Carbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N Carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 Carbenicillin Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N Carbidopa Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- CFOYWRHIYXMDOT-UHFFFAOYSA-N Carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 description 1
- 229960001704 Carbimazole Drugs 0.000 description 1
- OFZCIYFFPZCNJE-UHFFFAOYSA-N Carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 description 1
- 229960004587 Carisoprodol Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N Cathomycin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- RRYMAQUWDLIUPV-BXKDBHETSA-N Cefacetrile Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 RRYMAQUWDLIUPV-BXKDBHETSA-N 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N Cefalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N Cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960001139 Cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N Cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- SLAYUXIURFNXPG-CRAIPNDOSA-N Ceforanide Chemical compound NCC1=CC=CC=C1CC(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)CC(O)=O)CS[C@@H]21 SLAYUXIURFNXPG-CRAIPNDOSA-N 0.000 description 1
- 229960002682 Cefoxitin Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N Cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N Cefradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 229960002588 Cefradine Drugs 0.000 description 1
- 229960003202 Cefsulodin Drugs 0.000 description 1
- 229960000484 Ceftazidime Drugs 0.000 description 1
- 229960004755 Ceftriaxone Drugs 0.000 description 1
- 229960001668 Cefuroxime Drugs 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- 229940106164 Cephalexin Drugs 0.000 description 1
- 201000003884 Chagas disease Diseases 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- 229960005091 Chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-M Chlorosulfate Chemical compound [O-]S(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-M 0.000 description 1
- KKHPNPMTPORSQE-UHFFFAOYSA-N Chlorphenoxamine Chemical compound C=1C=C(Cl)C=CC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KKHPNPMTPORSQE-UHFFFAOYSA-N 0.000 description 1
- 229960004475 Chlortetracycline Drugs 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- TZFWDZFKRBELIQ-UHFFFAOYSA-N Chlorzoxazone Chemical compound ClC1=CC=C2OC(O)=NC2=C1 TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 description 1
- 229960003633 Chlorzoxazone Drugs 0.000 description 1
- 229940107137 Cholecystokinin Drugs 0.000 description 1
- 108010048926 Cholecystokinin Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N Chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241000434299 Cinchona officinalis Species 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N Clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N Clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N Clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 Clomifene Drugs 0.000 description 1
- 229940107775 Clomiphene Drugs 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 210000004246 Corpus Luteum Anatomy 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N Cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- 229960000978 Cyproterone Acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N Cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229940088961 DDAVP Drugs 0.000 description 1
- JJCQSGDBDPYCEO-XVZSLQNASA-N DIBEKACIN Chemical compound O1[C@H](CN)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N JJCQSGDBDPYCEO-XVZSLQNASA-N 0.000 description 1
- 229940093661 DL-Lactic Acid Drugs 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N Danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960001987 Dantrolene Drugs 0.000 description 1
- 229960000860 Dapsone Drugs 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- XXLZPUYGHQWHRN-RPBOFIJWSA-N Dehydroemetine Chemical compound COC1=C(OC)C=C2[C@@H]3CC(C[C@@H]4C5=CC(OC)=C(OC)C=C5CCN4)=C(CC)CN3CCC2=C1 XXLZPUYGHQWHRN-RPBOFIJWSA-N 0.000 description 1
- 229940119740 Deoxycorticosterone Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N Desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001908 Dexetimide Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229960003701 Dextromoramide Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N Dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N Diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003807 Dibekacin Drugs 0.000 description 1
- 229960003887 Dichlorophen Drugs 0.000 description 1
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophene Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N Dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N Diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- UXZFQZANDVDGMM-UHFFFAOYSA-N Diiodohydroxyquinoline Chemical compound C1=CN=C2C(O)=C(I)C=C(I)C2=C1 UXZFQZANDVDGMM-UHFFFAOYSA-N 0.000 description 1
- 229960001111 Diloxanide Drugs 0.000 description 1
- BDYYDXJSHYEDGB-UHFFFAOYSA-N Diloxanide furoate Chemical compound C1=CC(N(C(=O)C(Cl)Cl)C)=CC=C1OC(=O)C1=CC=CO1 BDYYDXJSHYEDGB-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N Diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N Diphenyl ether Chemical group C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 108010050169 Diphtheria Antitoxin Proteins 0.000 description 1
- 229960001188 Diphtheria Antitoxin Drugs 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 description 1
- 229940052760 Dopamine agonists Drugs 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 229960003722 Doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 1
- 229960003913 Econazole Drugs 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N Econazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N Emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Enkephalin L Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229960005309 Estradiol Drugs 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001348 Estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N Estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229940011871 Estrogens Drugs 0.000 description 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N Ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 1
- 229960000285 Ethambutol Drugs 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N Ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229960000445 Ethisterone Drugs 0.000 description 1
- CHNXZKVNWQUJIB-CEGNMAFCSA-N Ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 description 1
- CYTYCFOTNPOANT-UHFFFAOYSA-N Ethylene tetrachloride Chemical compound ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 1
- AOXRBFRFYPMWLR-XGXHKTLJSA-N Ethylestrenol Chemical compound C1CC2=CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](CC)(O)[C@@]1(C)CC2 AOXRBFRFYPMWLR-XGXHKTLJSA-N 0.000 description 1
- 229960003976 Etidocaine Drugs 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 229960005237 Etoglucid Drugs 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Etoglucid Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229960002428 Fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960004273 Floxacillin Drugs 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N Flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N Fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N Fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 Fluoxymesterone Drugs 0.000 description 1
- 229960000618 Fluprednisolone Drugs 0.000 description 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N Fluprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229940028334 Follicle Stimulating Hormone Drugs 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 229960002963 Ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229960004666 Glucagon Drugs 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004905 Gramicidin Drugs 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- IUAYMJGZBVDSGL-XNNAEKOYSA-N Gramicidin S Chemical compound C([C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 IUAYMJGZBVDSGL-XNNAEKOYSA-N 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N Griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- 229940037467 Helicobacter pylori Drugs 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- 229940084986 Human Chorionic Gonadotropin Drugs 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N Hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 Hydroxychloroquine Drugs 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102100014231 IGF1 Human genes 0.000 description 1
- 101700074337 IGF1 Proteins 0.000 description 1
- 102100005117 IGF2 Human genes 0.000 description 1
- 101700070236 IGF2 Proteins 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 229960004716 Idoxuridine Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229940120520 Iodoquinol Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N Ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229960000448 Lactic acid Drugs 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 229940115932 Legionella pneumophila Drugs 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 229940008250 Leuprolide Drugs 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- INUNXTSAACVKJS-NRFANRHFSA-N Levomoramide Chemical compound C([C@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-NRFANRHFSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N Lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005015 Local anesthetics Drugs 0.000 description 1
- 229940083877 Local anesthetics for treatment of hemorrhoids and anal fissures for topical use Drugs 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N MDL-62769 Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 101700074108 MLA Proteins 0.000 description 1
- 229940041033 Macrolides Drugs 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N Mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- 229960003439 Mebendazole Drugs 0.000 description 1
- 241000940612 Medina Species 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N Medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- XEEQGYMUWCZPDN-DOMZBBRYSA-N Mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- 229960004296 Megestrol Acetate Drugs 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 210000002752 Melanocytes Anatomy 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- JWDYCNIAQWPBHD-UHFFFAOYSA-N Mephenesin Chemical compound CC1=CC=CC=C1OCC(O)CO JWDYCNIAQWPBHD-UHFFFAOYSA-N 0.000 description 1
- ZMNSRFNUONFLSP-UHFFFAOYSA-N Mephenoxalone Chemical compound COC1=CC=CC=C1OCC1OC(=O)NC1 ZMNSRFNUONFLSP-UHFFFAOYSA-N 0.000 description 1
- UXYRZJKIQKRJCF-TZPFWLJSSA-N Mesterolone Chemical compound C1C[C@@H]2[C@@]3(C)[C@@H](C)CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C UXYRZJKIQKRJCF-TZPFWLJSSA-N 0.000 description 1
- 229960005272 Mesterolone Drugs 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N Mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 Mestranol Drugs 0.000 description 1
- IMWZZHHPURKASS-UHFFFAOYSA-N Metaxalone Chemical compound CC1=CC(C)=CC(OCC2OC(=O)NC2)=C1 IMWZZHHPURKASS-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- WRWBCPJQPDHXTJ-DTMQFJJTSA-N Methandriol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 WRWBCPJQPDHXTJ-DTMQFJJTSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N Methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 229940042048 Methimazole Drugs 0.000 description 1
- GNXFOGHNGIVQEH-UHFFFAOYSA-N Methocarbamol Chemical compound COC1=CC=CC=C1OCC(O)COC(N)=O GNXFOGHNGIVQEH-UHFFFAOYSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 1
- 229960003152 Metisazone Drugs 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 231100000782 Microtubule inhibitor Toxicity 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 229940114179 Mycobacterium bovis Drugs 0.000 description 1
- 229940010383 Mycobacterium tuberculosis Drugs 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- PHFJZKMLXDFUNB-UHFFFAOYSA-N N-[4-[(4-methylpyrimidin-2-yl)sulfamoyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NC1=NC=CC(C)=N1 PHFJZKMLXDFUNB-UHFFFAOYSA-N 0.000 description 1
- 101710008235 NTS Proteins 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N Nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 1
- 229950002366 Nafoxidine Drugs 0.000 description 1
- 229960000210 Nalidixic Acid Drugs 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N Nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960003255 Natamycin Drugs 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N Natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 229940052778 Neisseria meningitidis Drugs 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940053128 Nerve Growth Factor Drugs 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N Niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 229960001920 Niclosamide Drugs 0.000 description 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N Nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 description 1
- 229960000916 Niflumic Acid Drugs 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- RDXLYGJSWZYTFJ-UHFFFAOYSA-N Niridazole Chemical compound S1C([N+](=O)[O-])=CN=C1N1C(=O)NCC1 RDXLYGJSWZYTFJ-UHFFFAOYSA-N 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N Nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 Nitrofurantoin Drugs 0.000 description 1
- 229940053934 Norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N Norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N Norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 Norfloxacin Drugs 0.000 description 1
- 229960002950 Novobiocin Drugs 0.000 description 1
- WCWZMHMUOHSEPI-UHFFFAOYSA-N O=C1OCCCCOC(=O)C2=CC=C1C1=C2CCCC1 Chemical compound O=C1OCCCCOC(=O)C2=CC=C1C1=C2CCCC1 WCWZMHMUOHSEPI-UHFFFAOYSA-N 0.000 description 1
- 101710008205 OXT Proteins 0.000 description 1
- 102100017240 OXT Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000243981 Onchocerca Species 0.000 description 1
- 229960003941 Orphenadrine Drugs 0.000 description 1
- QVYRGXJJSLMXQH-UHFFFAOYSA-N Orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 description 1
- 229940092253 Ovalbumin Drugs 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N Oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 1
- ICMWWNHDUZJFDW-DHODBPELSA-N Oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 1
- 229960000625 Oxytetracycline Drugs 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N Oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N Oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 Oxytocin Drugs 0.000 description 1
- 102100008873 POMC Human genes 0.000 description 1
- 108060006375 POMC Proteins 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229940056360 Penicillin G Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940056367 Penicillin V Drugs 0.000 description 1
- 229960004448 Pentamidine Drugs 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N Pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Petidina Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- NONJJLVGHLVQQM-JHXYUMNGSA-N Pheneticillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C)OC1=CC=CC=C1 NONJJLVGHLVQQM-JHXYUMNGSA-N 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N Phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N Piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 229960000502 Poloxamer Drugs 0.000 description 1
- 229920001748 Polybutylene Polymers 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- FSVJFNAIGNNGKK-UHFFFAOYSA-N Praziquantel Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- WWYNJERNGUHSAO-XUDSTZEESA-N Previfem Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N Prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- INDBQLZJXZLFIT-UHFFFAOYSA-N Primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N Proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 229960005385 Proguanil Drugs 0.000 description 1
- 229940097325 Prolactin Drugs 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 1
- 229960000996 Pyrantel Pamoate Drugs 0.000 description 1
- AQXXZDYPVDOQEE-MXDQRGINSA-N Pyrantel pamoate Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 AQXXZDYPVDOQEE-MXDQRGINSA-N 0.000 description 1
- 229960001424 QUINESTROL Drugs 0.000 description 1
- PWZUUYSISTUNDW-VAFBSOEGSA-N Quinestrol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 PWZUUYSISTUNDW-VAFBSOEGSA-N 0.000 description 1
- 229960000948 Quinine Drugs 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Quinoform Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 102100000775 REN Human genes 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 229940030484 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Drugs 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- 229960000912 Stanozolol Drugs 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229940076185 Staphylococcus aureus Drugs 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229940076156 Streptococcus pyogenes Drugs 0.000 description 1
- 229960004739 Sufentanil Drugs 0.000 description 1
- 229960000973 Sulfadimethoxine Drugs 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N Sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N Sulfadimidine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- 229960004673 Sulfadoxine Drugs 0.000 description 1
- 229960000468 Sulfalene Drugs 0.000 description 1
- KXRZBTAEDBELFD-UHFFFAOYSA-N Sulfalene Chemical compound COC1=NC=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 KXRZBTAEDBELFD-UHFFFAOYSA-N 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N Sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 229960004936 Sulfamethoxypyridazine Drugs 0.000 description 1
- VLYWMPOKSSWJAL-UHFFFAOYSA-N Sulfamethoxypyridazine Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 VLYWMPOKSSWJAL-UHFFFAOYSA-N 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- QWCJHSGMANYXCW-UHFFFAOYSA-N Sulfaphenazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1 QWCJHSGMANYXCW-UHFFFAOYSA-N 0.000 description 1
- 229960001975 Sulfisomidine Drugs 0.000 description 1
- YZMCKZRAOLZXAZ-UHFFFAOYSA-N Sulfisomidine Chemical compound CC1=NC(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 YZMCKZRAOLZXAZ-UHFFFAOYSA-N 0.000 description 1
- 229940032484 Sulfisoxazole Drugs 0.000 description 1
- NEDPPCHNEOMTJV-UHFFFAOYSA-N Sulfoxone Chemical compound C1=CC(NCS(=O)O)=CC=C1S(=O)(=O)C1=CC=C(NCS(O)=O)C=C1 NEDPPCHNEOMTJV-UHFFFAOYSA-N 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N Suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 102000033174 TMPO Human genes 0.000 description 1
- 101710026709 TMPO Proteins 0.000 description 1
- VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 108010045759 Teprotide Proteins 0.000 description 1
- DAEAKVVPRJTPEQ-CSCXCSGISA-N Teprotide Chemical compound N([C@@H](CC=1[C]2C=CC=CC2=NC=1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCC(=O)N1 DAEAKVVPRJTPEQ-CSCXCSGISA-N 0.000 description 1
- 229950010186 Teprotide Drugs 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108090000242 Tetanus Antitoxin Proteins 0.000 description 1
- 229960005367 Tetanus Antitoxin Drugs 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 229960002372 Tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960004546 Thiabendazole Drugs 0.000 description 1
- BWBONKHPVHMQHE-UHFFFAOYSA-N Thiocarlide Chemical compound C1=CC(OCCC(C)C)=CC=C1NC(=S)NC1=CC=C(OCCC(C)C)C=C1 BWBONKHPVHMQHE-UHFFFAOYSA-N 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- 239000000898 Thymopoietin Substances 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 210000001541 Thymus Gland Anatomy 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- KKCIOUWDFWQUBT-AWEZNQCLSA-N Thyronine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-AWEZNQCLSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N Tiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 229960004659 Ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N Ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960005053 Tinidazole Drugs 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazolum Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 229960000707 Tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- FSKFPVLPFLJRQB-UHFFFAOYSA-N Tolperisone Chemical compound C=1C=C(C)C=CC=1C(=O)C(C)CN1CCCCC1 FSKFPVLPFLJRQB-UHFFFAOYSA-N 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 241000243774 Trichinella Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 229950009811 UBENIMEX Drugs 0.000 description 1
- 210000001635 Urinary Tract Anatomy 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 229960003165 Vancomycin Drugs 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 229940118696 Vibrio cholerae Drugs 0.000 description 1
- 229960003636 Vidarabine Drugs 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 108010015940 Viomycin Proteins 0.000 description 1
- GXFAIFRPOKBQRV-GHXCTMGLSA-N Viomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)N[C@@H](O)C1 GXFAIFRPOKBQRV-GHXCTMGLSA-N 0.000 description 1
- 229950001272 Viomycin Drugs 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N Zygomycin A1 Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- YCPOZVAOBBQLRI-PHDIDXHHSA-N [(2R,3R)-2,3-dihydroxy-4-methylsulfonyloxybutyl] methanesulfonate Chemical compound CS(=O)(=O)OC[C@@H](O)[C@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-PHDIDXHHSA-N 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- DLGSOJOOYHWROO-WQLSENKSSA-N [(Z)-(1-methyl-2-oxoindol-3-ylidene)amino]thiourea Chemical compound C1=CC=C2N(C)C(=O)\C(=N/NC(N)=S)C2=C1 DLGSOJOOYHWROO-WQLSENKSSA-N 0.000 description 1
- KYFFONAJKZUVQX-UHFFFAOYSA-N [Na].[Sb].C(C(S)C(S)C(=O)O)(=O)O Chemical compound [Na].[Sb].C(C(S)C(S)C(=O)O)(=O)O KYFFONAJKZUVQX-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N acyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- 229950006704 aldesulfone Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229940024142 alpha 1-Antitrypsin Drugs 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 108010041395 alpha-Endorphin Proteins 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001548 androgenic Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic Effects 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000702 anti-platelet Effects 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 230000001262 anti-secretory Effects 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 230000002965 anti-thrombogenic Effects 0.000 description 1
- 230000001147 anti-toxic Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- CPFJLLXFNPCTDW-BWSPSPBFSA-N benzatropine mesylate Chemical compound CS([O-])(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)[NH+]2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 CPFJLLXFNPCTDW-BWSPSPBFSA-N 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- 229960000254 bephenium Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940049154 botulinum antitoxin Drugs 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 125000004432 carbon atoms Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960003525 cefalexin Drugs 0.000 description 1
- 229960004292 ceforanide Drugs 0.000 description 1
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960003686 chlorphenoxamine Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 229960005228 clioquinol Drugs 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- XDJYMJULXQKGMM-RVYUQJQSSA-N colistin A Chemical compound CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O XDJYMJULXQKGMM-RVYUQJQSSA-N 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960003572 cyclobenzaprine Drugs 0.000 description 1
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 230000001085 cytostatic Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 229960000728 dehydroemetine Drugs 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000000249 desinfective Effects 0.000 description 1
- NFLWUMRGJYTJIN-PNIOQBSNSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-PNIOQBSNSA-N 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- 229960003654 desoxycortone Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- 229960003974 diethylcarbamazine Drugs 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 229960003061 dihydroemetine Drugs 0.000 description 1
- 229960000691 diiodohydroxyquinoline Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000002183 duodenal Effects 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940046080 endocrine therapy drugs Estrogens Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229960001460 ethylestrenol Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000003480 fibrinolytic Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 201000000628 gas gangrene Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 229940020899 hematological Enzymes Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000887 hydrating Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960002899 hydroxyprogesterone Drugs 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960000433 latamoxef Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 229950004592 liothyronine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229940064003 local anesthetic throat preparations Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229960001890 mecillinam Drugs 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960003861 mephenesin Drugs 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960000509 metaxalone Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960001833 methandriol Drugs 0.000 description 1
- 229940101475 methixene Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 229960002545 methylthiouracil Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960005103 metixene Drugs 0.000 description 1
- MJFJKKXQDNNUJF-UHFFFAOYSA-N metixene Chemical compound C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 MJFJKKXQDNNUJF-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229930014694 morphine Natural products 0.000 description 1
- 230000001002 morphogenetic Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- PCJGZPGTCUMMOT-UHFFFAOYSA-N neurotensin Chemical compound C1CCN(C(=O)C(CCCNC(N)=N)NC(=O)C(CCCNC(N)=N)NC(=O)C2N(CCC2)C(=O)C(CCCCN)NC(=O)C(CC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C2NC(=O)CC2)C1C(=O)NC(C(=O)NC(C(C)CC)C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 PCJGZPGTCUMMOT-UHFFFAOYSA-N 0.000 description 1
- 229960004300 nicomorphine Drugs 0.000 description 1
- 229960005130 niridazole Drugs 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229960000993 norethisterone Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003364 opioid Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- XCGYUJZMCCFSRP-UHFFFAOYSA-N oxamniquine Chemical compound OCC1=C([N+]([O-])=O)C=C2NC(CNC(C)C)CCC2=C1 XCGYUJZMCCFSRP-UHFFFAOYSA-N 0.000 description 1
- 229960000462 oxamniquine Drugs 0.000 description 1
- 229960000464 oxandrolone Drugs 0.000 description 1
- 101700057139 oxyT Proteins 0.000 description 1
- 125000005702 oxyalkylene group Chemical group 0.000 description 1
- 229960005244 oxymetholone Drugs 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- ZDDUXABBRATYFS-UHFFFAOYSA-F pentasodium;antimony(3+);4,5-dioxidobenzene-1,3-disulfonate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C([O-])=C1O[Sb]1OC2=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C=C2O1 ZDDUXABBRATYFS-UHFFFAOYSA-F 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229940083249 peripheral vasodilators Enzymes Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 229960004894 pheneticillin Drugs 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920001853 poly(butyleneterephthalate) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001042 poly(ÎŽ-valerolactone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000023 polynucleotide Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- IIQJBVZYLIIMND-UHFFFAOYSA-J potassium;antimony(3+);2,3-dihydroxybutanedioate Chemical compound [K+].[Sb+3].[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O IIQJBVZYLIIMND-UHFFFAOYSA-J 0.000 description 1
- 229960002957 praziquantel Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- 229960005179 primaquine Drugs 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- WYDUSKDSKCASEF-UHFFFAOYSA-N procyclidine Chemical compound C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCC1 WYDUSKDSKCASEF-UHFFFAOYSA-N 0.000 description 1
- 229960005253 procyclidine Drugs 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000003439 radiotherapeutic Effects 0.000 description 1
- 108091006066 receptor inhibitors Proteins 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- 230000003068 static Effects 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960002135 sulfadimidine Drugs 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- 229960001663 sulfanilamide Drugs 0.000 description 1
- 229960004818 sulfaphenazole Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 229960000103 thrombolytic agents Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960002171 tiocarlide Drugs 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- 229960005334 tolperisone Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000261 vasodilator Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- ZTHWFVSEMLMLKT-CAMOTBBTSA-N vidarabine monohydrate Chemical compound O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O ZTHWFVSEMLMLKT-CAMOTBBTSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- NXSIJWJXMWBCBX-NWKQFZAZSA-N α-Endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 NXSIJWJXMWBCBX-NWKQFZAZSA-N 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-MSH Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N γ-lactone 4-hydroxy-butyric acid Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 1
Description
æ¬çºæã¯ãç¹ã«è¬éåºã«é©ããŠããååæ£åŸ®ç²åæ¯éå£ãçããæ¹æ³åã³ããã€ã¹ã«é¢ããã
å€ãã®è¬éåºã¢ããªã±ãŒã·ã§ã³ã«ãããŠãç²åŸåã³ç²åŸååžã®å³å¯ãªå¶åŸ¡ãå¿
èŠãšããããäŸã¯ãã«ããŒãã«ããè¬ããªãªãŒã¹ããç²åã®éåºãç¹ã«èè
«çã®ãããªè
«çã®æ¯ç®¡ã®å±€ãžã®éåºãå¿
èŠãšããããšããã®äŸã§ããããã®è¬éåºã¢ããªã±ãŒã·ã§ã³ã«ãããŠãç²åã¯ãæãå°ããªæ¯çŽ°ç®¡å
ã§å¡æ 圢æãããšæ³å®ããããããæ¯çŽ°ç®¡ã现èå¢æ®ææ¢å€ã®ãããªè¬ããªãªãŒã¹ããåã¯å±æçβè¥ããã¯Î³æŸå°ç·ãäŸçµŠã§ãããããã¯ããã«ããŠã ã®ã¢ã»ãã«âã¢ã»ãããŒãã§ããŒããããç²åã«å¯Ÿããå Žåã§ãããç²åã®ãµã€ãºã¯ãåŠçã®å¹åã«éèŠãªåœ¹å²ãæãããç²åãããŸãã«å°ããå Žåããããã¯åŸªç°ããŠãä»ã®ãšãªã¢ãäŸãã°èºã«ããŸãã ãããããããããŸãã«å€§ããå Žåããããã¯æãå°ããªæ¯çŽ°ç®¡ã«å°éããªãã ãããåŸã£ãŠãæãå¹ççãªæ²»çã¯ãæ£ç¢ºäžã€äžæ§ã«èª¿è£œãããç²åã§éæãããããšã«ãªãã ããã
çå解æ§ããªããŒããåŸãããéåžžã«è¯ãèŠå®ãããç²åã«éããããã®ïŒã€ã®æ
æ§ã¯ã溶ããããããªããŒåã³è¬ãæã€æ¶²äœãæ¯çŽ°ç®¡ãéã£ãŠãäŸãã°å§çŽ ååã¯åæ§ã®ããã€ã¹ããã®æ¯åæ°ã®ä»äžã«ããæŒãããããã«ãã液äœãžã§ããã液滎ã«ãããæè¡ã䜿çšããããšã§ãããæ¯æ§ãªã·ã¹ãã ã¯ãç±³åœç¹èš±ïŒµïŒ³ïŒïŒïŒïŒïŒïŒïŒïŒïŒãïŒïŒïŒïŒïŒïŒïŒïŒïŒãåœéåºé¡å
¬éå
¬å ±ïŒ·ïŒ¯ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒãåã³ããŒã¯ã©ã³ããã«ããïŒïŒïŒïŒïŒïŒïŒªïŒïŒ£ïœïœïœïœïœïœ ïœ
ïœïœ
ïœïœïœ
ïŒïŒã®ïŒïŒé âïŒïŒé ã«èšèŒãããŠãããïŒïŒïŒïŒïŒïŒïŒïŒïŒã§ã¯ãå°åºããããšã¯ãããºã«çŽåŸããå°ãã液滎ãçããããšãå¯èœã«ããããã«ãä»å çãªäžæ¹ãžã®ååã¯å éãã€ããã®ã§ãããæ¯æ§ãªäžæ¹ãžã®åã®äŸã¯ãããªããã«ã¢ã«ã³ãŒã«ã®æº¶æ¶²ã®å
±ã®æµãã¹ããªãŒã ã§ãããïŒïŒïŒïŒïŒïŒïŒïŒïŒã«æ³šèšããã課é¡ã¯ã容æã«è©°ãŸããããçŽåŸïŒïŒÎŒïœããå°ããããºã«ããã®ç²åã®çæã§ãããïŒïŒïŒïŒïŒïŒïŒïŒïŒã«é瀺ãããæè¡ã¯ãææã®ãµã€ãºç¯å²ã®ç²åã®çç£ã®ãããããªãæ¿çž®ãªæº¶æ¶²ïŒïŒïŒ
ã®ããªããŒïŒã®äœ¿çšãå¯èœã«ãããããããªãããå¿
èŠã§ããä»å çãªåã®ãããçç£ã·ã¹ãã ã¯ãããè€éã«ãªããããã«ãïŒïŒÎŒïœããèããå°ããªç²åã®ããã®ãµã€ãºååžã¯ãïŒïŒÎŒïœãäžåãç²åã®ãµã€ãºååžã«å¯ŸããŠããããããåºããããå°ããªæ¶²æ»Žã®ã¹ããªãŒã ãåããããã¯ãããäŸãã°æ°Žæ§çžãå°å
¥ããããšãæå³ããé¡äŒŒã®ãã£ãªã¢ã»ã¹ããªãŒã ããïŒïŒïŒïŒïŒïŒïŒïŒïŒã§é瀺ãããŠããããã®æè¡ã¯ãæ¯èŒç倧ããªã«ãã»ã«ãããªãã¡ïŒïŒïŒÎŒïœãã倧ããªã«ãã»ã«ãçæããã
ïŒïŒÎŒïœã®ãµã€ãºãæã€ç²åã¯ãã©ãã¥ã¬ã·ã¥çïŒïŒïŒïŒïŒãProc.11thïœïœïŒïŒ³ïœïœïœïŒïŒ£ïœïœïœïœïœïœïŒïŒ²ïœ
ïœïŒïŒ³ïœïœïŒã«ãã説æãããããã«ãïŒïŒÎŒïœã®ãããããªã³ããã³ãã»ããºã«ã䜿çšããŠäœããããæ¬é¡æ现æžã«ãããŠãè£å©ã®å§åããçç£é床ã匷åããããã«ä»äžã§ãããåããªãµãŒãã°ã«ãŒãããã®ïŒµïŒ³ïŒïŒïŒïŒïŒïŒïŒïŒïŒã¯ãããªããŒåŸ®å°çäœãäœãããã«ããºã«ã液äœã«æ²ããŠãè£å©ã®å§åããªããããããªã³ããã³ãã»ã€ã³ã¯ãžã§ããæ¹æ³ã®äœ¿çšã説æããŠããã
ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒã¯ãåœæ¥è
ã«ç¥ãããŠãããã®ããå°ããªç²åãã奜ãŸããã¯è£å©ã®å§åãšçµã¿åãããŠãæ¯åæ°ãä»äžããã浞ããããããºã«ã䜿çšããŠãçç£ã§ããããšã説æãããåŽåºãããä¹³æ¿æ¶²æ»Žã®æ³šææ·±ãåçž®ã¯ãïŒÎŒïœãšåçšåºŠã®å°ããªç²åãåŸããããŒããŒçã«ããïŒïŒïŒïŒïŒïŒïŒColloids and Surfaces 289, 96é -104é ïŒã«ã説æãããŠããããã«ãååæ£ããŒã¿ã«ãã»ã«ãåŸãããã説æãããŠããã·ã¹ãã ã«ãããŠãè£å©ã®å§åã¯ãããé«ãåŽåºçãå¯èœã«ããã ãã§ãªããããã€ã¹ã®ããºã«ã®è©°ãŸãã劚ãããä»å çãªå§åã䜿ãããªãå Žåãããªä¹³é
žã®ãããªããªããŒã¯åŽåºãããã¹ãæµäœãšé£ç¶çžãšã®éã®ã€ã³ã¿ãŒãã§ãŒã¹ã§æ²æ®¿ããŠããŸãã ãããïŒïŒïŒïŒïŒïŒïŒïŒïŒåã¯ïŒµïŒ³ïŒïŒïŒïŒïŒïŒïŒïŒïŒã«èª¬æãããããã»ã¹ããäœãããªããŒæ¿åºŠã䜿çšããããã»ã¹ãïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒã«èª¬æãããŠããŠãä¹³æ¿æ¶²æ»Žã®ããå°ããªãµã€ãºãžã®åçž®ãšãªãã
åè¿°ã®åŸæ¥æè¡ã®ææžã«èšèŒãããŠãããã¹ãŠã®æ¹æ³ã¯ãä¹³æ¿æ¶²æ»Žåã³çµæãšããŠçããç²åãå®å®ãããããã«ãããªããã«ã¢ã«ã³ãŒã«ã®ãããªæ·»å ç©ãå©çšãããããªããã«ã¢ã«ã³ãŒã«ã®è¿œå ã¯ãçå解æ§ããªããŒããããªããŒç²åã®èª¿è£œã«ïŒã€ã®å¹æãæã€ãä¹³æ¿æ¶²æ»Žåã³ãããã圢æãããç²åã®äž¡æ¹ãå®å®ãããã
ãµã€ãºåã³åäžæ§ã®è«ç¹ã®ä»ã«ãç²åãã€ã³ã¯ãžã§ããããéã®ä»ã®èª²é¡ã¯ãåããæµäœå
ã§ã®ä¹³æ¿æ¶²æ»Žã®èæ§ã§ããã溶åªæœåºã®éãããæ··ãã¯ãéåžžã«ç©ããã«èµ·ãããªããã°ãªããããããªããã°å®¹æã«æ¶²æ»Žã厩å£ããŠããŸããããŒããŒçã®(2006) Colloids & Surfaces, Physicochem. Eng.Aspects289,96é -104é ã§ã¯ã埮ç²åããããºã«ãããªãªãŒã¹ã®åŸãããæ··ããããªãã·ã¹ãã ã説æããã
æ¬çºæã®ç¹ã«å¥œé©ãªæ
æ§ã¯ãæ·»ä»ã®ç¬ç«è«æ±é
åã³åŸå±è«æ±é
ã«ãããŠè¿°ã¹ããããåŸå±ã¯ã¬ãŒã ã®ç¹åŸŽã¯ãæ確ã«è«æ±é
ã«åã«è¿°ã¹ãããã ãã§ãªããé©åã«ç¬ç«ã¯ã¬ãŒã ã®ç¹åŸŽåã³ä»ã®åŸå±ã¯ã¬ãŒã ã®ç¹åŸŽãšçµã¿åããããŠãããã
æ¬çºæã®äžã€ã®æ
æ§ã¯ãããªããŒç²åã®çç£ã®ããã®ããã€ã¹ã«é¢ããåœè©²ããã€ã¹ã¯ãä¹³æ¿ïŒïŒïŒãä¿æããããã®ç¬¬ïŒã®ãªã¶ãŒãïŒïŒïŒãšãåããæµäœïŒïŒïŒãä¿æããããã®ç¬¬ïŒã®ãªã¶ãŒãïŒïŒïŒãšã第ïŒã®ãªã¶ãŒãïŒïŒïŒãæºããããŠãããšããåèšåããæµäœïŒïŒïŒã«æµžããã液滎ãåèšåããæµäœïŒïŒïŒãžçŽæ¥åŽåºå¯èœã«ããå°ãªããšãäžã€ã®ããºã«ïŒïŒïŒãæã€åŽåºã¢ãžã¥ãŒã«ãšãåèšããºã«ïŒïŒïŒãã第ïŒã®ãªã¶ãŒãïŒïŒïŒå
ã®åèšåããæµäœïŒïŒïŒãžåŽåºããããšãã液滎ãåŸããé¢ïŒïŒïŒã«æ²¿ã£ãŠç§»åããããã«ã第ïŒã®ãªã¶ãŒãïŒïŒïŒãžãªã³ã¯ããåã¯äœçœ®ã¥ããããåœè©²åŸããé¢ïŒïŒïŒãšãæããåèšåŸããé¢ïŒïŒïŒã¯ãåçŽçã«å§ãŸãïŒïŒåºŠããïŒïŒåºŠã®éã®è§åºŠã§çµãã段éçã«å€åããåŸæãæã€ã
ä»ã®æ
æ§ã«ãããŠãæ¬çºæã¯ããã®ããã€ã¹ãå©çšããŠãããªããŒç²åã調補ããããã®æ¹æ³ã«é¢ããã
ç¹å®ã®æ
æ§ã«ãããŠãæ¬çºæã¯ãïŒÎŒïœãšïŒïŒïŒÎŒïœãšã®éã®ç¯å²ã®ãµã€ãºãæã€ååæ£ãããã²ã«ããªããŒåŸ®ç²åã調補ããããã®æ¹æ³ã«é¢ããåèšåŸ®ç²åã¯çç©æŽ»æ§å€ãæããæ¬çºæã«ããããã€ã¹ãå©çšãããåœè©²æ¹æ³ã¯ãïœïŒåèšçç©æŽ»æ§å€ãæããããªããŒã圢æãããããã²ã«ã®ä¹³æ¿ã調補ããã¹ããããšãïœïŒè£å©ã®å§åã䜿çšããæ¯åãä»äžããŠã氎溶æ§ã®åããæµäœã«æµžãããããºã«ïŒïŒïŒããã¹ãããïœïŒã®åèšä¹³æ¿ã®æ¶²æ»ŽãåŽåºïŒååºïŒããã¹ããããšãïœïŒæº¶åªã®é€å»ãšãåèšæ¶²æ»Žã®æ°Žã§ã®é£œåãšã確å®ã«ããæéã§ãåèšåããæµäœå
ã«åèšæ¶²æ»Žã移åå¯èœã«ããããšã«ãããåèšæ¶²æ»ŽãèšããŸããŠç¡¬åããã¹ããããšãæããåœè©²ã¹ãããïœïŒã«ãããèšããŸããŠç¡¬åããã¹ãããã¯ãåèšåããæµäœå
ã§ç²åãå°ãªããšãïŒïŒåºŠã®åŸæãæã€åŸããé¢ã移åã§ããããšã«ããå®æœãããã
æ¬çºæã®æ¬æ
æ§ã«ããæ¹æ³ã®äžã€ã®å®æœäŸã«ãããŠãããªããŒã®æ¿åºŠã¯ïŒâïŒïŒ
ã®éã«ãããããºã«ã®çŽåŸã¯ïŒâïŒïŒÎŒïœã®éã«ããã液滎ãåããæµäœå
ã§ç§»åããæéã¯ïŒãïŒïŒç§ã§ããã
ãããã®æ¹æ³ã®å
·äœäŸã«ãããŠãåããæµäœå
ã®åŸ®ç²åã®æ¹æãªãã«ã¹ãããïŒïœïŒã¯ç¢ºå®ã«ãããã
ãããã®æ¹æ³ã®ä»ã®å
·äœäŸã«ãããŠãã¹ãããïŒïœïŒã®èšããŸããŠç¡¬åããã¹ãããã¯ãåããæµäœå
ã§ç²åãå°ãªããšãïŒïŒåºŠã®åŸæãæã€åŸããé¢ã移åã§ããããšã«ããå®è¡ãããã
ãããã®æ¹æ³ã®ããã«ä»ã®å®æœäŸã«ãããŠãåŸããé¢ã¯ã段éçã«å€åããåŸæãæã€ã
æ¬çºæã®å¥ã®æ
æ§ã¯ãïŒÎŒïœãšïŒïŒïŒÎŒïœãšã®éãç¹ã«ïŒÎŒïœãšïŒïŒÎŒïœãšã®éã®ç¯å²ã®ãµã€ãºãæã€ååæ£ããªããŒåŸ®ç²åã調補ããæ¹æ³ã§ãã£ãŠããããã®åŸ®ç²åãçç©æŽ»æ§å€ãæããåœè©²æ¹æ³ã¯ãçç©æŽ»æ§å€ã®ä¹³æ¿åã³ããªããŒã®æº¶æ¶²ã調補ããã¹ãããïŒïœïŒãšãè£å©ã®å§åã䜿çšãæ¯åãä»äžããŠãåããæµäœã«æµžããããããºã«ããã¹ãããïŒïœïŒã®ä¹³æ¿ã®æ¶²æ»Žåã¯ç²åã泚å
¥ããã¹ãããïŒïœïŒãšãç²åãåŸããé¢äžã®åããæµäœå
ã§ç§»åã§ããããšã«ããããããã®ç²ååã¯æ¶²æ»Žã埮ç²åã«ç¡¬åããã¹ãããïŒïœïŒãšãæããåèšåŸããé¢ã®åŸæã¯æ®µéçãªå€æŽåŸæã§ãããåãã€ã³ãã®åŸæãå°ãªããšãïŒïŒåºŠãç¹ã«å°ãªããšãïŒïŒåºŠã®è§åºŠãæã€æ¹æ³ã«é¢ããã
ãããã®æ¹æ³ã®å
·äœäŸã«ãããŠãããªããŒã¯ããããã²ã«ã»ããªããŒã§ããããããã®å®æœäŸã«ãããŠã䜿çšãããããªããŒããããã²ã«ã»ããªããŒã§ããæ¬çºæã®æ¬æ
æ§ã«ããæ¹æ³ã®æŽã«ç¹å®ã®å®æœäŸã«ãããŠãã¹ãããïŒïœïŒãã溶åªã®é€å»åã³æ°Žãšã®é£œåã確å®ã«ããæéã®éãåããæµäœå
ã§ç²åãåŸããé¢äžã移åã§ããã¹ããããæãããšæ³å®ãããã
äžèšã®æ¹æ³ã®å
·äœäŸã«ãããŠãä¹³æ¿ã®ãããã²ã«ã»ããªããŒã®æ¿åºŠã¯ãããºã«çŽåŸã®çŽåŸã®ïŒïŒïŒ
ãç¹ã«ïŒïŒïŒ
ãè¶
ããçŽåŸãæã€ãããã²ã«ç²åãåŸãããã«èª¿ç¯ãããã
äžèšããæ¹æ³ã®ä»ã®å
·äœäŸã«ãããŠãä¹³æ¿ã®ãããã²ã«ã»ããªããŒã®æ¿åºŠã¯ãïŒïŒ
ããäžã§ããã
æ¬çºæã®æ¹æ³ã®ä»ã®å®æœäŸã«ãããŠãä¹³æ¿ã®ãããã²ã«ã»ããªããŒã®æ¿åºŠã¯ïŒïŒïŒãïŒïŒïŒïŒ
ã®éã«ãããããºã«ã¯ïŒïŒÎŒïœãšïŒïŒÎŒïœãšã®éã®çŽåŸãæã€ã
æ¬çºæã®æ¹æ³ã®å
šãŠã®å
·äœäŸã«ãããŠãçç©æŽ»æ§å€ã¯ãçæ°Žæ§ã§ããã
æ¬çºæã®æ¹æ³ã®ä»ã®å®æœäŸã«ãããŠãçç©æŽ»æ§å€ã¯èŠªæ°Žæ§çç©æŽ»æ§å€ã§ãããäžèšæ¹æ³ã®ã¹ãããïŒïœïŒã¯ã芪氎æ§çç©æŽ»æ§å€ã®æ°Žæº¶æ¶²åã³ããªããŒã®æº¶æ¶²ã®æ²¹äžæ°Žä¹³å€ã調補ããã¹ããããæããã
æ¬çºæã®æ¹æ³ã®å
·äœäŸã«ãããŠã埮ç²åã¯ãïŒïŒÎŒïœãšïŒïŒÎŒïœãšã®éã®ç¯å²ã®ãµã€ãºãæã€ã
æ¬çºæã®æ¹æ³ã®å
·äœäŸã«ãããŠãããªããŒã¯ãããªïŒé
žåãšãã¬ã³ïŒãã¬ãã¿ã«é
žå¡©åã³ããªïŒïŒãïŒâããã¬ã³ïŒãã¬ãã¿ã«é
žå¡©ïŒïŒ°ïŒ¥ïŒ§ïŒŽïŒïŒ°ïŒ¢ïŒŽïŒå
±éåäœã§ããã
åŸããé¢ã䜿çšãããæ¬çºæã®æ¹æ³ã®å
·äœäŸã«ãããŠãããºã«ããåŽåºãããç²åãïŒãïŒïŒç§ã®éã®æéãåŸããé¢ã«æ²¿ã£ãŠç§»åããããã«ãåŸããé¢ã®é·ãåã³åŸæãæ§æãããã
æ¬çºæã®æ¹æ³ã®ä»ã®å
·äœäŸã«ãããŠãæ¹æ³ã¯ãã¹ãããïŒïœïŒã®åŸãããæ··ããããšã«ããç²åãæŽã«å
ããããè¿œå ã¹ãããïŒïœïŒãæããã
æ¬çºæã®æ¹æ³ã®å
·äœäŸã«ãããŠãããºã«ã¯ãïŒïŒÎŒïœããå°ããªçŽåŸãæã€ã
æ¬çºæã®æ¹æ³ã®å
·äœäŸã«ãããŠãããªããŒã¯ãããã²ã«ã»ããªããŒã§ãããåœè©²æ¹æ³ã¯åããæµäœå
ã«å®å®å€ããªãå Žåã«å®æœãããã
æ¬çºæã®å¥ã®æ
æ§ã¯ãïŒÎŒïœãšïŒïŒïŒÎŒïœãšã®éãç¹ã«ïŒÎŒïœãšïŒïŒÎŒïœãšã®éã«ãµã€ãºãæã€ååæ£ããªããŒåŸ®ç²åã®æ¯éå£ãäŸçµŠãããããã®ç²åãäžã€ä»¥äžã®çç©æŽ»æ§å€ãæããããããã®æ¯éå£ã¯ãäžèšã®æ¹æ³ã«ããå
¥æã§ããã
æ¬çºæã®ååæ£ããªããŒåŸ®ç²åã®æ¯éå£ã®å
·äœäŸã«ãããŠãããªããŒã¯ãããã²ã«ã»ããªããŒã§ãããïŒïŒïŒ
ãè¶
ãã埮ç²åã¯ãæ¯éå£ã®å¹³åå€ã®ïŒïŒïŒÎŒïœå
ã«å
¥ãçŽåŸãæã€ã
ååæ£ããªããŒåŸ®ç²åã®æ¯éå£ã®å
·äœäŸã«ãããŠããããã²ã«ã»ããªããŒã¯ãïŒïŒ°ïŒ¢ïŒŽå
±éåäœã§ããã
æ¬çºæã®ååæ£ããªããŒåŸ®ç²åã®æ¯éå£ã®ä»ã®å
·äœäŸã«ãããŠãïŒïŒïŒ
ãè¶
ãã埮ç²åã¯ãæ°å¹³åçŽåŸã®ïŒïŒ
以å
ã«å
¥ãã
æ¬çºæã«ããäŸçµŠãããååæ£ããªããŒåŸ®ç²åã®æ¯éå£ã®å
·äœäŸã«ãããŠããããã®åŸ®ç²åã¯ã芪氎æ§çç©æŽ»æ§å€ãæããããåã¯çæ°Žæ§çç©æŽ»æ§å€ãæããã
æ¬çºæã¯ãŸããè¬éåºã®ããäžè¿°ã®ãããªååæ£åŸ®ç²åæ¯éå£ã®äœ¿çšãå«ããæ¬çºæã¯ãŸããäžè¿°ã®ãããªååæ£åŸ®ç²åæ¯éå£ãæãããå»è¬åçµæç©ãäŸçµŠããã
æ¬çºæã®ããã€ã¹ã®å
·äœäŸã«ãããŠã段éçã«å€åããåŸæã¯ãïŒïŒåºŠãšïŒïŒåºŠãšã®éã®è§åºŠã§çµããã
æ¬çºæã®äžèšåã³ä»ã®ç¹æ§ãç¹åŸŽåã³å¹æã¯ãäŸãã°ãæ¬çºæã®åçãäŸç€ºããæ·»ä»ã®å³é¢ãåç
§ããŠã以äžã®è©³çŽ°ãªèª¬æããæããã«ãªãã ããããã®èª¬æã¯ãæ¬çºæã®ç¯å²ãå¶éããããšãªããäŸç€ºã®ããã«ã ãäžãããããäžèšã«åŒçšãããå³ã¯ãæ·»ä»ã®å³é¢ãåç
§ããã
ç°ãªãå³ã«ãããŠãåãåç
§ç¬Šå·ã¯ãåãã§ãããé¡äŒŒããèŠçŽ ãæãã
æ¬çºæã¯ãç¹å®ã®å³é¢ãåç
§ããŠå
·äœçå®æœäŸã«é¢ããŠèª¬æãããããæ¬çºæã¯ãããå®æœäŸã«å¶éããããè«æ±é
ã«ãã£ãŠã®ã¿å¶éããããè«æ±é
ã®äœãã®åç
§ç¬Šå·ããç¯å²ãå¶éãããã®ãšããŠè§£éãããªãã説æãããå³é¢ã¯ãæš¡åŒçã§ééå®çã§ãããå³ã«ãããŠãèŠçŽ ã®ããã€ãã®ãµã€ãºã¯ãèªåŒµãããŠã説æã®äŸ¿å®äžã¹ã±ãŒã«ã©ããã«æãããŠããªããçšèªããæããããæ¬èª¬æåã³è«æ±é
ã§äœ¿çšãããå Žåãããã¯ä»ã®èŠçŽ åã¯ã¹ããããé€å€ããªããäŸãã°ãïœãåã¯ãïœïœãããïœïœïœ
ããåæ°åè©ã«æããŠãå®å è©åã¯äžå®å è©ã䜿çšããããšããã§ã¯ãäœãä»ã®ç¹å®ã®æèšããªãããŠããªããªãã°ããã®åè©ã®è€æ°åœ¢ãå«ãã
æŽã«ãæ现æžåã³è«æ±é
ã«ãããçšèªã第ïŒã®ããã第ïŒã®ããã第ïŒã®ãçã¯ãåæ§ã®èŠçŽ éãåºå¥ããããã«äœ¿çšãããã®ã§ãã£ãŠãå¿
ãããã·ãŒã±ã³ã·ã£ã«åã¯çµæçé çªã説æãããããšããããã§ã¯ãªãããã䜿çšãããçšèªãé©åœãªç¶æ³ã®äžã§äº€æå¯èœã§ãããæ¬é¡æ现æžã«ãããŠèª¬æãããæ¬çºæã®å®æœäŸã¯ãæ现æžã§èª¬æããåã¯äŸç€ºããã以å€ã®å¥ã®ã·ãŒã±ã³ã¹ã®åäœãå¯èœã§ããããšãç解ãã¹ãã§ããã
以äžã®çšèªåã¯å®çŸ©ã¯ãåã«ãæ¬çºæãç解ããéã®æŽå©ã®ããã«æäŸãããããããã®å®çŸ©ã¯ãåœæ¥è
ã«ããç解ãããããçãç¯å²ãæã€ãšãããã¹ãã§ã¯ãªãã
æ¬æ现æžã§äœ¿çšãããçšèªã埮ç²åãã¯ãïŒÎŒïœãšïŒïŒïŒÎŒïœãšã®éã®çŽåŸãæã€ç²åãããã
çšèªãçç©æŽ»æ§å€ãã¯ãæŠããŠãçççè¥ããã¯è¬ççãªæŽ»æ§ç©è³ªãåã¯çççç°å¢ã®çç©è£œå€ããåãåºãããåã¯çç©è£œå€å
ã§æ€åºã«é©ããŠããç©è³ªãæãã
çšèªã芪氎æ§ã§ãããã¯ãã氎溶æ§ã®ããšå矩èªãšããŠæ¬é¡æ现æžã§äœ¿çšãããæ°Žåååã³å¢å€§ããã氎溶æ§ãåŒãå¯ããåŸåã説æããããã«ãæ¬é¡æ现æžã§äœ¿çšããããïŒïŒïŒã°ã©ã 以äžã®è¬å€ãã倧æ°å§ã®äžã§ïŒïŒâã§ãªããã«æ°ŽïŒïŒïŒïŒïŒïœïœïŒïœïœïŒåœãã溶ããå Žåãçç©æŽ»æ§å€ã¯æ°Žæº¶æ§ã§ãããšèæ
®ããããè€æ°ã®åŸ®ç²åãæããšãæ¬é¡æ现æžã§äœ¿çšãããçšèªãååæ£ãã¯ããµã€ãºååžã®æšæºåå·®ãïŒïŒïŒ
æªæºã§ããããšã瀺ãã
æ¬æ现æžã§äœ¿çšãããçšèªããããã²ã«ãã¯ãããªããŒã»ãã§ãŒã³ã®ç©çååŠçãªç¹æ§ãããããã¯ãŒã¯å
ã®å
±æçµååã¯éå
±æçµåã®çµåãã¡ã€ã³ã®ãããæŽãªãèšåŒµãé²æ¢ãããã€ã³ããŸã§ããããã¯ãŒã¯ãæ°Žãšã³ã³ã¿ã¯ããããšèšåŒµãããããªèªç¶åã¯åæããªããŒã»ãã§ãŒã³ã®ãããã¯ãŒã¯ããããããªããŒã®æ°Žåå¯èœãªã°ã«ãŒãã®éã«äŸåããŠãè±æ°Žãããã²ã«ã¯ããã¡ã¯ã¿ïŒãïŒïŒã§ãéåžžã¯çŽïŒããçŽïŒã®éã®ãã¡ã¯ã¿ïŒæ¬æ现æžã«ãããŠãæ°ŽåçšåºŠãšåŒã°ããïŒã§æ°Žåã®éãããªã¥ãŒã çã«èšåŒµããã
æ¬çºæã¯ãè¬éåºã«é©ããŠããæ°èŠåã³æ¹è¯ããã埮ç²ååã³ããããçç£ããæ¹æ³ãæäŸããã
æ¬çºæã®äžæ
æ§ã¯ãäžã€ä»¥äžã®çç©æŽ»æ§å€ãæããè€æ°ã®ååæ£ããªããŒåŸ®ç²åã調補ããæ¹æ³ãæäŸããããã詳ããã¯ã埮ç²åã¯ãïŒÎŒïœããïŒïŒïŒÎŒïœãç¹ã«ïŒÎŒïœããïŒïŒÎŒïœãç¹ã«ïŒïŒÎŒïœããïŒïŒÎŒïœã®éã®å¹³åãµã€ãºãæã€ãããå€ãã®å
·äœäŸã«ãããŠã埮ç²åã¯ãïŒïŒÎŒïœããïŒïŒÎŒïœã®å¹³åãµã€ãºãæã€ã
æ¬çºæã®æ¹æ³ã«ãããšã芪氎æ§çç©æŽ»æ§å€ãæããããªããŒåŸ®ç²åã¯ãã€ã³ã¯ãžã§ããæè¡ã䜿çšããŠåœ¢æããããïŒïŒïŒïŒïŒïŒïŒïŒïŒã«èª¬æãããŠãããããªã€ã³ã¯ãžã§ããã®æ¢ç¥ã®æ¹æ³ã®äžå©ãªç¹ã¯ãã€ã³ã¯ãžã§ãããããä¹³æ¿æ¶²æ»Žã®èæ§ã§ããã溶åªæœåºã®éã®æ¹æã¯ãéåžžã«ç©ããã«èµ·ãããªããã°ãªããããããªããã°æ¶²æ»Žã容æã«åŽ©å£ããã
æ¬çºæã«ãããšãã€ã³ã¯ãžã§ããããæè¡ã䜿çšãããããã«ããããªããŒåŸ®ç²åã液äœïŒåããæµäœïŒå
ã«æ»Žäžã§ããããšã«ãããåœè©²ããªããŒåŸ®ç²åãå
ãïŒç¡¬åïŒããããåèšåããæµäœã¯ãç·©è¡å¯èœã§ãã£ãŠãå¡©é¡ãçé¢æŽ»æ§å€ã¹ã¿ãã©ã€ã¶ãïŒãïŒïŒè¥ããã¯ïŒïŒïŒ
ãŸã§ã®ææ©ååç©åã¯ä»ã®æ·»å ç©ã®ãããªæ·»å åæç©ãå«ãããšãã§ãã氎溶液ã§ããããã®æåã®èšåŒµåã³ïŒåã¯ç¡¬åã®éãåããæµäœã¯ãäŸãã°ç²åå士ã®è¡çªã«ããçããæ©æ¢°çæå·ãåé¿ããããã«éåžžæ¹æãããªãã容åšã®é©åœãªé«ããéžæããããšã«ãããä¹³æ¿æ¶²æ»Žãéåã«ããç¹å®ã®è·é¢èœäžãããã®ããšã«ããããçšåºŠå
ããªãããšã確å®ã«ããããã®åŸãä¹³æ¿æ¶²æ»Žã¯å®¹åšããé€å»ãããæŽãªã硬åã®ããã«æ¹æã§ããã
æ¬çºæã®äžæ
æ§ã«ãããšã埮ç²åã®ã€ã³ã¯ãžã§ããã®æ¹æ³åã³ããã€ã¹ã¯ããã®æè¡ã«ãããããºã«ããæŸåºãããä¹³æ¿æ¶²æ»Žã¯ãäžæ¹ã«åŸæããé¢ãæã€åããæµäœå
ã§æ¥è§ŠããŠããã®é¢ã«è»¢ããèœã¡ããåã¯ã¹ã©ã€ãããªãããèšåŒµåã³ïŒåã¯å
ããªãå§ãããæŽã«ç¹ã«ãåŸããé¢ã¯ã段éçãªå€æŽåŸæãæã€ãå®éãéåäžã§èœäžãã代ããã«ãä¹³æ¿æ¶²æ»Žãåããæµäœå
ã§æ®µéçãªå€æŽåŸæã転ãããåã¯ã¹ã©ã€ãã§ããããšã«ãããä¹³æ¿æ¶²æ»Žã¯ãç¹å®ã®æéã®éãåããæµäœå
ã§çæããå¢å€§ãããåäžæ§ãæã€ååæ£ç²åãåŸãããããšãããã£ãã
åèšåŸããé¢ã®é·ãã¯å€åã§ãããšãããã液滎ã®ãµã€ãºã«ãã決å®ãããã ãããçãããåŸæã®æ§é åã³åŸæã®ããã«äœ¿çšãããç©è³ªã¯ãèšåŒµåã³ïŒåã¯ç¡¬åå€ç²åã®åå¿ïŒããšãã°ç²ãïŒã«åœ±é¿ãããã®ç©è³ªã®çæ°Žæ§ã¯ãå¹æãæã¡ã液滎ãåŸããé¢ãžç§»åããããã«å¿
èŠãªæéãæŽã«å¶åŸ¡ããããã«åœæ¥è
ã«ãã調æŽã§ãããå
·äœäŸã«ãããŠãè¡šé¢ã®é·ãåã³ãã®åŸæã¯ãåŸæã«æ²¿ã£ãŠä¹³æ¿æ¶²æ»Žã®è»¢ããåã¯ã¹ã©ã€ãã«ããéåãçŽïŒç§ãšïŒïŒç§ãšã®éã§åããããã«ãä¹³æ¿æ¶²æ»Žã®æŒžé²çãªæžéã確å®ã«ããããã«èšèšããããå
·äœäŸã«ãããŠãåŸæã«æ²¿ã£ãç²åã®åããïŒïŒç§æªæºåã¯ïŒç§æªæºã§ãããããšããæ¡ä»¶ãéžæããããå
·äœäŸã«ãããŠãåŸããé¢ã®é·ããïŒïœïœãšïŒïœïœåã¯ãã以äžãšã®éã«ããããšãæ³å®ãããã
å
·äœäŸã«ãããŠãåŸããé¢ã®åŸæã¯åºå®ãããããã詳ããã¯ãé¢ã®åŸæã¯ãïŒïŒãïŒïŒåºŠãïŒïŒãïŒïŒåºŠåã¯ïŒïŒãïŒïŒåºŠã®éã§ãããåŸããé¢ã¯ããªãã¢ãäŸãã°çŽç·ã®ç®¡ã§ãããããéåžžã¯ãåŸããé¢ã¯ãïŒæ¶²æ»ŽãåŸããé¢ãšæ¥è§Šããããåã¯åŸããé¢ãžèœã¡ãããšãå¯èœã«ããïŒããºã«äžã®äœçœ®ããåéã®ããã®ç¬¬ïŒã®å®¹åšãŸã§å»¶åšãããªãã·ã§ã³ã§æŽã«ãåŸããã埮ç²åã®åŠçãè¡ããããºã«ã®éå£éšãšåŸããé¢ãšã®éã®è·é¢ïŒåã¯ã液滎ãããºã«ããåŸããé¢ã«å°éããããã«å¿
èŠãªæéïŒã¯ãæ¬çºæã®æ¹æ³ã®ããã«æ³å®ãããæé©ç¡¬åïŒèšåŒµè·é¢ïŒèšåŒµæéïŒã®ç¯å²å
ã«å«ãŸãããå°ãªããšãããºã«ã®ç¹å®äœçœ®ã«ãããŠãïŒäŸãã°éåã®çµæãšããŠãåã¯ããºã«ãšåŸããé¢ãšã®éã®çŽçµã«ããïŒããºã«ããæŸåºãããä¹³æ¿æ¶²æ»Žãèªåçã«åŸããé¢ãšæ¥è§Šãããããªæ
æ§ã§ãåŸããé¢ã¯ã容åšå
ã«å®å
šã«åã¯éšåçã«é
眮ã§ããæŸåºããºã«ã浞ãããããåã¯å®¹åšã«é£çµãã§ããã
å
·äœäŸã«ãããŠã段éçãªå€æŽåŸæãæã€åŸããé¢ãæ³å®ããããç¹ã«ã段éçã«å€åããéãåŸæã¯å°ãªããšãïŒïŒåºŠã®åŸæãç¹ã«åŸæã®åãã€ã³ãã§å°ãªããšãïŒïŒÂ°ã®åŸæãç¶æãããšæ³å®ããããéåžžãåŸããé¢ã®åŸæã¯ãïŒïŒÂ°ïŒããºã«ããã®åçŽèœäžã«å¯Ÿå¿ããïŒããå°ãªããšãïŒïŒÂ°ãç¹ã«åŸããé¢ã®çµããïŒåŸ®ç²åãåéãããæãäŸãã°åé槜ïŒïŒïŒïŒã§å°ãªããšãïŒïŒÂ°ãŸã§æ®µéçã«å€åããã
å
·äœäŸã«ãããŠãç¹ã«æ¡åŒµããé·ãã®è¡šé¢ãæ³å®ãããæã§ã¯ãåŸããé¢ã¯ãã«ãŒããããåã¯å°ããªããªã¥ãŒã ã§ãå¿
èŠãªé·ããã€ããããã«èºæ圢ã§ããã
åŸããé¢ã¯ãå¹³åŠã§ããããåã¯æ¶²æ»Žãè¡šé¢ããèœã¡ãã®ãé²æ¢ããããã«ãã«ãŒãããçžãæãããå
·äœäŸã«ãããŠãè¡šé¢ã¯ãåããæµäœã®ãããªæµäœïŒïŒïŒïŒãå«ãåé槜ïŒïŒïŒã«æ¥ç¶ãã管åã¯æºã§ããã
åŸããé¢ã転ãããåã¯ã¹ã©ã€ãããåŸã«ãä¹³æ¿æ¶²æ»Žã¯ãååã«ç¡¬åãããŠïŒèšåŒµããããªãã·ã§ã³ã§èŠåçã«æ¹æããããšã«ããæŽã«åŠçããããåŸã£ãŠã液滎ã¯ãåé槜ïŒïŒïŒã«åéã§ãããå ããŠãåã¯ãããã¯ã液滎ã¯ãåããæµäœããåãåºãããå埩ã§ããã
æ¬çºæã®ååçãªåŠçã¹ãããã¯ãåŽåºããã液滎ãžã®æå·ãåé¿ããå¹æãæã¡ãç¹å®ã®å®æœäŸã«ãããŠãä¹³æ¿æ¶²æ»Žåã¯åœ¢æããã埮ç²åãå®å®ãããããã«éåžžçšããããããªããã«ã¢ã«ã³ãŒã«ã®ãããªæ·»å ç©ããªãå Žåã«å®æœãããã
æ¬çºæã®æ¹æ³åã³ããŒã«ã¯ãçç©æŽ»æ§å€ã®éåºã®ããã®åŸ®ç²åã®çæã«ãããŠç¹ã«èå³ãããããã£ãŠããªãã·ã§ã³ã§äžã€ä»¥äžã®çç©æŽ»æ§å€ãæããã
æ¬çºæã®äžã€ã®å®æœäŸã«ãããšãæ¬çºæã®ããŒã«åã³æ¹æ³ããçæ°Žæ§çç©æŽ»æ§å€ãæãã埮ç²åã®çæã®ããã«äœ¿çšãããããã®å®æœäŸã«ãããšãçæ°Žæ§çç©æŽ»æ§å€ã¯ãä¹³æ¿ã調補ããããã«ææ©æº¶å€ãžããªããŒãšå
±ã«æ··åããããã®åŸæ¬çºæã®æ¹æ³ã«åŸã£ãŠã€ã³ã¯ãžã§ããããããããªããŒåã³çæ°Žçãªè¬å€ã®ä¹³æ¿ã調補ããæ¹æ³ã¯ãåœæ¥è
ã«è¯ãç¥ãããŠããã
æ¬çºæã®ä»ã®å®æœäŸã«ãããšãæ¬çºæã®æ¹æ³åã³ããŒã«ã¯ã芪氎æ§åã¯æ°Žæº¶æ§çç©æŽ»æ§å€ãæãã埮ç²åã®çæã®ããã«äœ¿çšãããã芪氎æ§çç©æŽ»æ§å€ãæããããªããŒåŸ®ç²åã¯ãäºéä¹³åæè¡ã䜿çšããŠåœ¢æãããã第ïŒã®ã¹ãããã«ãããŠã芪氎æ§çç©æŽ»æ§å€ã氎溶液ã«æº¶ããããŠãïŒïŒïŒïŒ
ã®æ°Žã®å¯æº¶æ§ãæã€ãžã¯ããã¡ã¿ã³ã®ãããªãæ°Žãšæ··ãããªããåã¯æ°ŽïŒïŒåã¯ïŒïŒ
æªæºïŒã®éãããå¯æº¶æ§ãæã€ç¬¬ïŒã®æº¶åªã«å°å
¥ããŠããããªããŒã®æº¶æ¶²ãšæ··åãããäž»èŠãªæ²¹äžæ°Žåä¹³æ¿ïŒä¹³å€ïŒã圢æãããäž»èŠãªä¹³å€ã¯ç¬¬ïŒã®ä¹³å€ã圢æããããã«æ°Žæ§ç¬¬ïŒã®æº¶åªã«å ããããå質åãç¶ç¶ãããã第ïŒåã³ç¬¬ïŒã®æº¶åªã¯ã第ïŒã®æº¶åªã第ïŒã®æ°Žæ§æº¶åªãšæ··ãããªããéšåçã«æ··ããããã«éžæãããããããªããŒã¯ç¬¬ïŒã®æº¶åªãšã¯æ··ãããªããæ²¹äžæ°Žåä¹³å€ã®å°å
¥ã®åŸã第ïŒã®æº¶åªã¯ã第ïŒã®æº¶åªãžç§»åããããã®ããã«ããŠã氎溶æ§çç©æŽ»æ§å€ãæããè€æ°ã®ã¯ã¬æ§œãå«ãããªããŒåŸ®ç²åãåŸããããããã¯ã溶åªã®èžçºåã¯æœåºã«ãããã©ããŒããããæ¬çºæã«ãããšãå¢å€§ãããåäžæ§ã®åŸ®ç²åãåŸãããããã®ããŒã«åã³æ¹æ³ãäŸçµŠããããæ¬çºæã®æ¹æ³åã³ããŒã«ã«ãããŠãæ°Žæ§çžã®åŸ®ç²åã¯ãæ°Žæ§åããæµäœïŒïŒïŒã®äžã§ããºã«ããåŸããé¢ã«èœãšãããããã詳ããã¯ãäžè¿°ã®ããã«ãåŸããåŸæã段éçãªå€æŽåŸæãæã€ã
åŸã£ãŠãæ¬çºæã®æ¹æ³ã¯ã芪氎æ§åã¯çæ°Žæ§çç©æŽ»æ§å€ãæãã埮ç²åã®çç£ãæ³å®ããããäžè¿°ã®ããã«ãæ žé
žãçæ°Žåç©ãåã³äžè¬ã«ã¿ã³ãã¯è³ªåã³ããããã¯ã氎溶æ§åã¯èŠªæ°Žæ§ã§ãããäºéä¹³å€æè¡ã䜿çšããŠã埮ç²åã«æŠããŠæé©ã«çµã¿èŸŒãŸãããããããªãããããããã®ãããããå«ãçæ°Žçãªè¬ïŒäŸãã°ããããå
ã®ã¢ããé
žã®ããªãã®å²åãçæ°ŽçãªåŽéãæ
æãããšãïŒã¯ãæ¬çºæã®æ¹æ³ã«ãããã£ãŠã€ã³ã¯ãžã§ããããããã®ä¹³å€ã調補ããããã«ãçŽæ¥ãææ©æº¶å€ã®ããªããŒãšå
±ã«å解ã§ãããåŸã£ãŠãæ¬çºæã¯ãæ¬çºæã«ããååŸã§ãã埮ç²åãå«ãå»è¬åçµæç©ãå«ãã
ã¿ã³ãã¯è³ªåã³ããããã®ç¹çŽ°ãããã¿ãŠãæ¬çºæã®æ¹æ³åã³ããŒã«ãããªããŒã«ã¿ã³ãã¯è³ªåã³ãããããããŒããããã®ã«ç¹ã«æå¹ã§ããã«ãããããããã¿ã³ãã¯è³ªåã¯ãããã以å€ã®ç©è³ªãšããªããŒãããŒããããããšãããã¡ããæ³å®ããããäŸãã°ãå°ããªååãè質ããªãå€ç³é¡ãããªãã¯ã¬ãªããåã³ã¢ã³ãã»ã³ã¹ã»ãã¯ã¬ãªããïŒéºäŒåæ²»çè¬å€ïŒã§ããçç©æŽ»æ§å€ãæ³å®ãããããã£ãŠãçµã¿èŸŒãŸããŠãããæ¯æ§ãªçç©åŠçã«æŽ»æ§ãªè¬å€ã¯ãéãããããéã¿ã³ãã¯è¬ãå«ããéåæ§è³ªã®è¬ãçµã¿èŸŒãããšã¯æ¬çºæã®ç¯å²å
ã§å¯èœã§ãããããŸããïŒïŒïŒïŒæªæºåã¯ããã«ïŒïŒïŒæªæºã®æ¯èŒçå°ããªååéã®è¬ãçµã¿èŸŒãããšãæ¬çºæã®ç¯å²å
ã§å¯èœã§ããã
åŸã£ãŠãæ¬çºæã®ç¶æ³ã®äžã§çç©æŽ»æ§å€ãšããŠã®äœ¿çšã®ããã«æ³å®ãããåæç©ã¯ãæ²»ççåã¯äºé²å¹æãæã€åæç©ãå«ããåèšåæç©ã¯ãçµç¹ã®æé·ã现èæé·ã现èååã«åœ±é¿ãããåã¯åå ããåæç©ã§ãããããå
ç«åå¿ã®ãããªçç©åŠçã¢ã¯ã·ã§ã³ãåŒãèµ·ãããåæç©ã§ãããããåã¯äžã€ä»¥äžã®çç©åŠçããã»ã¹ã«ãããŠäœããã®ä»ã®åœ¹å²ãæãããåæç©ã§ããããééå®çãªãªã¹ãã®äŸã¯ãæèè¬ïŒæèå€ãæãŠã€ã«ã¹è¬åã³æçèè¬ãå«ãïŒãæãŠã€ã«ã¹è¬ãå¶çè¬ãããã³ãã³æå¶å€ãåè¡æ 圢æè¬å€ãè¡æ 溶解å€ãç·ç¶çŽ 溶解è¬å€ãè¡ç®¡æ£çž®æå¶å€ãã«ã«ã·ãŠã ãã£ãã«é®ææäœãè¡ç®¡æ¡åŒµè¬ãæé«è¡å§çè¬å€ãæèè¬ãæçç©è³ªãè¡šé¢ã°ãªã³ãããã€ã³å容äœã®æå¶å€ãæè¡å°æ¿è¬å€ã现èåè£é»æ¢æ§ç©è³ªã埮å°ç®¡æå¶å€ãååæ³è¬å€ãã¢ã¯ãã³æå¶å€ïŒæå¶å€ãå代è¬ç©è³ªãæå¢æ®å€ïŒåè管圢æè¬å€ãå«ãïŒãå¶çååŠçæ³è¬ãæççã¹ããã€ãåã¯éã¹ããã€ãæ§ã®æççå€ãæ¹é ããå
ç«æå¶è¬å€ãæé·ãã«ã¢ã³æ®æç©è³ªãæé·å åãããŒããã³äœçšè¬ãã©ãžãªæ²»çè¬å€ã现èå€ãããªãã¯ã¹éšåãé»å®³è¬ãéé¢ã©ãžã«ã«ã¹ã«ãã³ãžã£ããã¬ãŒãåå€ãé
žåé²æ¢å€ãåããªã¡ã©ãŒãŒåã³å
ååŠæ§æ²»çè¬å€ãå«ãã
äžèšã«ç€ºããããã«ãæ¬çºæã«ãããã£ãŠããªããŒãããŒãããããã«äœ¿çšã§ããåæç©ã®ç¹å®ã®ã°ã«ãŒãã¯ãããããåã³ã¿ã³ãã¯è³ªã«ãã圢æãããååãšããŠãæ¬çºæã«ãã£ãŠããããã®åŠäœãªãçš®é¡ãçµã¿èŸŒãŸãããæ¯èŒçå°ããªããããã¯ãã¢ããé
žã®æ°ã«ããïŒäŸãã°ïŒïŒãžïŒãïŒïŒããªïŒãïŒïŒããã©ïŒããããïŒãšåŒã°ãããã¢ããçµåã®æ¯èŒçå°ããªæ°ãæã€ããããã¯ããªãªãŽããããïŒæ倧ïŒïŒã®ã¢ããé
žïŒãšãåŒã°ããäžæ¹ãæ¯èŒçé«ãæ°ïŒïŒïŒãè¶
ããã¢ããé
žïŒãæã€ããããã¯ããªããããåã¯ã¿ã³ãã¯è³ªãšåŒã°ãããã¢ããé
žæ®åºéã®ããªããŒã§ããããšã«å ããŠãç¹å®ã®ã¿ã³ãã¯è³ªã¯ãããããåå
æ§é ã«ããæŽã«ç¹åŸŽä»ããããã¢ããçµåã«ããå¿
ãããååŠçã«çµåããããšããããã§ã¯ãªããŠãéé»ååã³ãã¡ã³ãã«ã¯ãŒã«ã¹åã®ãããªåœæ¥è
ã«æŠããŠç¥ãããŠããåã«ããçµåã§ããå€ãã®ããªããããã®éåäœã«ããç¹åŸŽä»ããããŠããããæ¬æ现æžã§çšããããçšèªãããããã¿ã³ãã¯è³ªåã¯ãããã®æ··åç©ã¯ãäžè¿°ããå¯èœæ§ããã¹ãŠå«ãã¹ãã§ããã
éåžžãã¿ã³ãã¯è³ªåã³ïŒåã¯ããããã¯ããã®çç©æŽ»æ§ã«åºã¥ããŠéžæããããéžæãããããªããŒã®ã¿ã€ãã«äŸåããŠãæ¬ããã»ã¹ã«ããååŸã§ããçç£ç©ã¯ãã¿ã³ãã¯è³ªåã³ããããã®åŸæŸã«éåžžã«é©ããŠãããç¹å®ã®å®æœäŸã§ã¯ãã¿ã³ãã¯è³ªåã¯ããããã¯ãæé·å åã§ããã
ãããããã¿ã³ãã¯è³ªãåã¯ããŒããããããªããŒã«å¥œé©ã«å«ãŸããã¿ã³ãã¯è³ªåã¯ãããããæããå®åšç©ã®ä»ã®äŸã¯ãããã«éå®ããããã®ã§ã¯ãªãããäžèšã®ãã®ãå«ããå
ç«åæ§ããããåã¯å
ç«åæ§ã¿ã³ãã¯è³ªãå«ãã
ãžãããªã¢æ¯çŽ åã³ç Žå·é¢šæ¯çŽ ã®ãããªæ¯çŽ ã
ã¢ãããŠã€ã«ã¹ãã€ãã·ã¥ã¿ã€ã³âããŒãŠã€ã«ã¹ãåèçãŠã€ã«ã¹ãåèçãŠã€ã«ã¹ããã«ãã¹ãŠã€ã«ã¹ãâãâïŒãâãã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ãæ¥æ¬è³çãŠã€ã«ã¹ã麻ç¹ãŠã€ã«ã¹ãããããŒããŠã€ã«ã¹ããã©ãã¯ãœãŠã€ã«ã¹å±ãããªãªãŠã€ã«ã¹ãçç¬ç
ãŠã€ã«ã¹ã颚ç¹ãŠã€ã«ã¹ãã¯ã¯ã·ãã¢ïŒå€©ç¶çïŒãŠã€ã«ã¹åã³é»ç±ç
ãŠã€ã«ã¹ã®ãããªãŠã€ã«ã¹ã®äžéšåã¯ãŠã€ã«ã¹è¡šé¢æåã
çŸæ¥å³èãããªã³ãã¯ã¿ãŒãããªãç Žå·é¢šèãã³ãªããã¯ããªã¢ãžãããªã¢ã倧è
žèããã¢ãã£ã«ã¹å±ã€ã³ãã«ãšã³ã¶ãã¯ã¬ãã·ãšã©å±çš®ãã¬ãžãªãã©ã»ãã¥ãŒã¢ãã£ã©èããã€ã³ãã¯ããªãŠã âããã¹ãããèããã€ã³ãã¯ããªãŠã çµæ žãæ·èãé«èçèãããããŠã¹çš®ãç·è¿èããµã«ã¢ãã©å±çš®ãèµ€ç¢èçš®ãé»è²ãããŠçèãåè¿ã¬ã³ãµçèããããªãªå±ã³ã¬ã©åã³ãã¹ãèã®ãããªçŽ°èã®äžéšåã¯çŽ°èè¡šé¢æåã
äžæ¥ç±ãã©ãªã¢åè«ïŒãã©ãªã¢ïŒãç±åž¯ç±ãã©ãªã¢åè«ïŒãã©ãªã¢ïŒãåµåãã©ãªã¢åè«ïŒãã©ãªã¢ïŒãåæ¥ç±ãã©ãªã¢åè«ïŒãã©ãªã¢ïŒãç±åž¯ãªãŒã·ã¥ããã¢ïŒãªãŒã·ã¥ããã¢çïŒããããã¡ã³ãªãŒã·ã¥ããã¢ïŒãªãŒã·ã¥ããã¢çïŒããã©ãžã«ãªãŒã·ã¥ããã¢ïŒãªãŒã·ã¥ããã¢çïŒãããªãããœãŒãããŒãã»ã³ã¹ïŒç ãç
ïŒãã¬ã³ãã¢ããªãããœãŒãïŒç ãç
ïŒãã¯ã«ãŒãºããªãããœãŒãïŒã·ã£ã¬ã¹ç
ïŒããã³ãœã³äœè¡åžè«ïŒäœè¡åžè«çïŒããã«ãã«ãäœè¡åžè«ïŒäœè¡åžè«çïŒãæ¥æ¬äœè¡åžè«ïŒäœè¡åžè«çïŒãã»ã³ã¢ãŠãã¥ãŠïŒææ¯è«ç
ïŒãã¹ããã³ã®ãã€ãã¹é€è«ïŒé€è«ïŒãåäºæè
žé€è«ïŒé€è«ïŒãã¢ã¡ãªã«é€è«ïŒé€è«ïŒããã³ã¯ããã糞ç¶è«ïŒãã£ã©ãªã¢çïŒããã¬ãŒç³žç¶è«ïŒãã£ã©ãªã¢çïŒããã¢ç³žç¶è«ïŒãã£ã©ãªã¢çïŒããã£ãã¿ããã糞ç¶è«ïŒãã£ã©ãªã¢çïŒãã¡ãžãè«ïŒãã£ã©ãªã¢çïŒåã³åæ糞ç¶è«ïŒãã£ã©ãªã¢çïŒã®ãããªå¯çè«ã®äžéšåã¯çŸæ£ãåŒãèµ·ãããŠããå¯çè«ã®ãã¡è¡šé¢æåã
ïœïŒ§ãïœïŒ¡ãïœïŒãæçç¬ç
å
ç«ã°ãããªã³åã³æã¯ã¯ã·ãã¢å
ç«ã°ãããªã³ã®ãããªå
ç«ã°ãããªã³ã
ãããªãã¹èææ¯çŽ ããžãããªã¢ææ¯çŽ ãã¬ã¹å£çœææ¯çŽ ãç Žå·é¢šææ¯çŽ ã®ãããªææ¯çŽ ã
å£è¹ç«ã«å¯ŸããŠå
ç«åå¿ãèªçºããæåã
åµèåºæ¿ãã«ã¢ã³ãããã©ã¯ãã³ãã¢ã³ãžãªã²ãã³ãäžç®çŽ°èå¢æ®å åãã«ã«ã·ããã³ããšãªãããã€ãšãã³ãç²ç¶è
ºåºæ¿æ§æŸåºãã«ã¢ã³ãã€ã³ã·ã¥ãªã³ãæé·ãã«ã¢ã³ãã€ã³ã·ã¥ãªã³æ§æé·å åïŒåã³ïŒãéªšæ Œã®æé·å åããã絚æ¯æ§ãŽãããããã³ãé»äœåœ¢æãã«ã¢ã³ãç¥çµæé·å åãå¯è
ç®è³ªåºæ¿ãã«ã¢ã³ïŒïŒ¡ïŒ£ïŒŽïŒšïŒãé»äœåœ¢æãã«ã¢ã³æŸåºãã«ã¢ã³ïŒïŒ¬ïŒšïŒ²ïŒšïŒãå¯ç²ç¶è
ºãã«ã¢ã³ïŒïŒ°ïŒŽïŒšïŒãç²ç¶è
ºåºæ¿ãã«ã¢ã³æŸåºãã«ã¢ã³ïŒïŒŽïŒ²ïŒšïŒãããœãã¬ãã·ã³ãã³ã¬ã·ã¹ãããã³åã³å¯è
ç®è³ªåºæ¿ãã«ã¢ã³æŸåºãã«ã¢ã³ã®ãããªãã«ã¢ã³é¡åã³æé·å åïŒã€ã³ã¿ãŒãã§ãã³ãã€ã³ã¿ãŒãã€ãã³ãã³ãããŒåºæ¿å ååã³è
«çå£æ»å åã®ãããªãµã€ãã«ã€ã³ïŒãŠããããŒãŒãè
èãã©ã¹ããã²ã³æŽ»æ§å€ã®ãããªç·ç¶çŽ 溶解é
µçŽ ïŒåã³ãããã€ã³ïŒ£ã第å åã第å åã第å ååã³ã¢ã³ãããã³ãã³ïŒ©ïŒ©ïŒ©ã®ãããªååºå åã
ä»ã®ã¿ã³ãã¯è³ªåã¯ããããã®äŸã¯ãã¢ã«ããã³ãå¿æ¿æ§ãããªãŠã å©å°¿å åãã¬ãã³ãéé
žåç©ãžã¹ã ã¿ãŒãŒãαïŒã§ããâæããªãã·ã³ãèºçé¢æŽ»æ§å€ã¿ã³ãã¯è³ªããã·ãã©ã·ã³ããã¹ã¿ãã³ãã·ã¯ãã¹ããªã³ãÎŽç¡ç èªçºããããïŒïŒ€ïŒ³ïŒ©ïŒ°ïŒããšã³ãã«ãã£ã³ãã°ã«ã«ãŽã³ãã°ã©ãã·ãžã³ãã¡ã©ãã³åœ¢æ现èæå¶å åããã¥ãŒããã³ã·ã³ããªãã·ãã·ã³ããœãã¹ã¿ãã³ãããããããè¡æž
èžè
ºå åããã¢ã·ã³ãããã«ã¢ã«ãã£ã³ãã¡ããšã³ã±ãã¡ãªã³ãããããã°ãªã«ã³ããµã¿ãšãã£ã³ããµã€ã¢ããšãã³ããã£ããªã³å解çæç©ãéãšã³ã±ãã¡ãªã³âαâãšã³ãã«ãã£ã³ãçæ®è
ºåºæ¿ãã«ã¢ã³æŸåºãã«ã¢ã³ããã€ãããªããαâïŒïŒ³ïŒšåã³ã¡ãã±ãã¡ããã
ã¢ã«ãã¬ã¿ãã³ããã«ãªããŠã©ã·ã«ãã¢ã ãµã¯ãªã³ãããããã·ã«ã«ããããã¢ã¹ãã©ã®ããŒãŒãã€ãã¹ãã¡ããããã¬ãªãã€ã·ã³ããã ã¹ãã³ããã¹ã«ãã¡ã³ãã¡ã«ãã¡ã©ã³ãã¯ãã©ã ãã·ã«ãã¡ã«ã«ããããªã³ãã¯ãã«ã»ã¡ã¿ã»ãã³ãã¡ããã¬ããµãŒããã·ã¹ãã©ãã³ããã€ããã€ã·ã³ãã·ã¯ããã¹ãã¡ãããããã«ã«ããžã³ãã·ã¿ã©ãã³ããããã·ãããã«ã«ããžã³ãããªããããã¯ãããã€ã·ã³ãããªã°ã¢ãã³ãããŠãã«ãã·ã³ããã¬ãªã¹ã«ãã¡ã³ããããœã«ãã·ã³ãããªãã©ã¹ãã¡ããããšã¹ãã©ã ã¹ãã³ããã³ãã©ã¹ãã³ããšãã°ã«ã·ãããã³ã¯ãªã¹ãã³ããšããã·ãããã³ãã·ã³åã³ãã¯ãªã¿ãã»ã«ã®ãããªå¶çè¬ã
æèè¬ã¯ä»¥äžãæããã
ã¢ã³ãã·ãªã³ãããã·ãªã³ãã¢ã¢ãã·ã·ãªã³ããªããµã·ãªã³ãã¢ãºãã·ãªã³ãããã·ãªã³ïŒ§ãã«ã«ããã·ãªã³ãããã·ãªã³ïŒ¶ããžã¯ãããµã·ãªã³ããã§ããã·ãªã³ãããããµã·ãªã³ãããã©ã·ãªã³ãã¡ã·ãªãã ãã¹ã«ããã·ãªã³ãã¡ãã·ãªã³ããã«ã«ã·ãªã³ãã¡ãºãã·ãªã³ãã»ãã¡ãã¹ããªã³ïŒã»ãã¡ã¯ããŒã«ãã»ãã¡ããã³ãã»ãã¡ãããã·ã«ãã»ãã¡ããªã³ãã»ãã¡ãã³ããŒã«ãã»ãã©ãžã³ãã»ãã¡ããªãžã³ãã»ãã¹ããžã³ãã»ãã¡ãŸãªã³ãã»ãã¿ãžãžã ãã»ãã©ã©ãããã»ãããªã¢ããœã³ãã»ãã©ãã·ãã³ãã»ãããã·ã ãã»ãã¡ã»ããªã«ãã©ã¿ã¢ãã»ãåã³ã»ãã¡ã¬ãã·ã³ã®ãããªæçç©è³ªãã¢ãã«ã·ã³ãããªãã€ã·ã³ããžãã«ã·ã³ãã«ããã€ã·ã³ãã²ã³ã¿ãã€ã·ã³ãç¡«é žããã«ãã€ã·ã³ãã«ããã€ã·ã³ãããã©ãã€ã·ã³ã®ãããªã¢ããã°ãªã³ã·ããã¢ã³ãããªã·ã³ïŒ¢ãããããªã·ã³ããã·ãã©ã·ã³ããã€ã¹ã¿ãã³ãã¯ãªã³ããã€ã·ã³ãããªããã·ã³ãã³ãªã¹ãã³ããããã€ã·ã³ããšãªã¹ããã€ã·ã³ãã¹ãã¯ãããã€ã·ã³ããªã³ã³ãã€ã·ã³ããã³ã³ãã€ã·ã³ã®ãããªãã¯ãã©ã€ããã¯ãã«ããã©ãµã€ã¯ãªã³ããªãã·ããã©ãµã€ã¯ãªã³ããã¡ã¯ããµã€ã¯ãªã³ãããªããã©ãµã€ã¯ãªã³ãããã·ãµã€ã¯ãªã³ãããã©ãµã€ã¯ãªã³åã³ãããµã€ã¯ãªã³ããã©ãµã€ã¯ãªã³ãã¯ãã©ã ãã§ãã³ãŒã«ããªãã¡ãã€ã·ã³ããªãã¡ã³ãã·ã³åã³ãã¢ã³ãã§ãã³ãŒã«ã®ãããªä»ã®æçç©è³ªã
ã¢ã³ãã·ãªã³ãããã·ãªã³ãã¢ã¢ãã·ã·ãªã³ããªããµã·ãªã³ãã¢ãºãã·ãªã³ãããã·ãªã³ïŒ§ãã«ã«ããã·ãªã³ãããã·ãªã³ïŒ¶ããžã¯ãããµã·ãªã³ããã§ããã·ãªã³ãããããµã·ãªã³ãããã©ã·ãªã³ãã¡ã·ãªãã ãã¹ã«ããã·ãªã³ãã¡ãã·ãªã³ããã«ã«ã·ãªã³ãã¡ãºãã·ãªã³ãã»ãã¡ãã¹ããªã³ïŒã»ãã¡ã¯ããŒã«ãã»ãã¡ããã³ãã»ãã¡ãããã·ã«ãã»ãã¡ããªã³ãã»ãã¡ãã³ããŒã«ãã»ãã©ãžã³ãã»ãã¡ããªãžã³ãã»ãã¹ããžã³ãã»ãã¡ãŸãªã³ãã»ãã¿ãžãžã ãã»ãã©ã©ãããã»ãããªã¢ããœã³ãã»ãã©ãã·ãã³ãã»ãããã·ã ãã»ãã¡ã»ããªã«ãã©ã¿ã¢ãã»ãåã³ã»ãã¡ã¬ãã·ã³ã®ãããªæçç©è³ªãã¢ãã«ã·ã³ãããªãã€ã·ã³ããžãã«ã·ã³ãã«ããã€ã·ã³ãã²ã³ã¿ãã€ã·ã³ãç¡«é žããã«ãã€ã·ã³ãã«ããã€ã·ã³ãããã©ãã€ã·ã³ã®ãããªã¢ããã°ãªã³ã·ããã¢ã³ãããªã·ã³ïŒ¢ãããããªã·ã³ããã·ãã©ã·ã³ããã€ã¹ã¿ãã³ãã¯ãªã³ããã€ã·ã³ãããªããã·ã³ãã³ãªã¹ãã³ããããã€ã·ã³ããšãªã¹ããã€ã·ã³ãã¹ãã¯ãããã€ã·ã³ããªã³ã³ãã€ã·ã³ããã³ã³ãã€ã·ã³ã®ãããªãã¯ãã©ã€ããã¯ãã«ããã©ãµã€ã¯ãªã³ããªãã·ããã©ãµã€ã¯ãªã³ããã¡ã¯ããµã€ã¯ãªã³ãããªããã©ãµã€ã¯ãªã³ãããã·ãµã€ã¯ãªã³ãããã©ãµã€ã¯ãªã³åã³ãããµã€ã¯ãªã³ããã©ãµã€ã¯ãªã³ãã¯ãã©ã ãã§ãã³ãŒã«ããªãã¡ãã€ã·ã³ããªãã¡ã³ãã·ã³åã³ãã¢ã³ãã§ãã³ãŒã«ã®ãããªä»ã®æçç©è³ªã
ã¹ã«ãã©ã³ã¢ããã»ãµã«ãã¡ãã€ã¢ãžã³ãã¹ã«ãã¡ã¡ããŸãŒã«ãã¹ã«ãã¡ãžã¡ããã·ã³ãã¹ã«ãã¡ã¡ãããµãŸãŒã«ãã¹ã«ãã¡ãžããžã³ãã¹ã«ãã¡ã¡ããã·ããªããžã³ãã¹ã«ãã¡ãã©ãŸãŒã«ãã¹ã«ãã¡ãã§ããŸãŒã«ãã¹ã«ãã¡ã¬ã³ãã¹ã«ãã£ãœããžã³ãã¹ã«ãã¡ã¡ã©ãžã³ãã¹ã«ãã¡ã¡ãããµãŸãŒã«åã¯ã¹ã«ãã¡ã¡ãããŒã«ãæã€ããªã¡ãããªã åã³ã¹ã«ãã£ãœããµãŸãŒã«ã®ãããªååŠçæ³æ²»çè¬ã
ã¡ã¿ã³ã¢ãã³ããããã³é¡ïŒãã«ããããµã·ã³ãã·ãããµã·ã³ïŒãããªãžãã·ã³é
žããããååç©ïŒããããã©ã³ãã€ã³ãããã«ãã€ããŒã«ïŒåã³ãªããœãªã³é
žã®ãããªå°¿è·¯æ¶æ¯å€ã
ã¡ãããããŸãŒã«ã®ãããªå«æ°æ§ææçã®ããã®è¬ã
ã¢ãããµã«ãã«é
žãã€ãœãã¢ãžããã·ã¯ãã»ãªã³ããªãã¡ã³ãã·ã³ããšã¿ã³ãããŒã«ãããªã«ã«ãªãããšããªãããåã³ãã€ãªãã€ã·ã³ã®ãããªçµæ žã®ããã®è¬ã
ã¢ãããªãŸã³ããªãã¡ã³ãã·ã³ãã¯ããã¡ãžãã³ããããªãŠã ã»ã¹ã«ãããœã³åã³ãžã¢ãããžãã§ãã«ã¹ã«ãã³ïŒïŒ€ïŒ€ïŒ³ããããœã³ïŒã®ãããªãã³ã»ã³ç
ã®ããã®è¬ã
ã¢ã³ãããªã·ã³ïŒ¢ãã±ãã³ããŸãŒã«ãã¯ãããªããŸãŒã«ããã³ããŸãŒã«ããšã³ããŸãŒã«ããã¿ãã€ã·ã³ããã«ã·ãã·ã³ããã€ã¹ã¿ãã³åã³ã°ãªã»ãªãã«ãã³ã®ãããªæçèè¬ã
ã¢ã·ã¯ããã«ãã€ãã¯ã¹ãŠãªãžã³ãã¢ãã³ããžã³ãã¡ããµãŸã³ãã·ã¿ã©ãã³ãããã©ãã³åã³ã¬ã³ã·ã¯ããã«ã®ãããªæãŠã€ã«ã¹è¬ã
ã¯ãããã³ããšãŒãã»ãããŒã«ãã¯ãªãªãããŒã«ãã¡ãããããŸãŒã«ããããããšã¡ãã³ãããã¢ãã€ã·ã³ããžãããµããããããšãŒãããããŸãŒã«åã³ãšã¡ãã³ã®ãããªã¢ã¡ãŒãçã®ååŠçæ³ã
ã¯ãããã³ãããªã¡ã¿ãã³ãããããã·ã¯ãããã³ããããŒããã¡ãããã³ãã¹ã«ãã¡ããã·ã³ïŒããªã¡ã¿ãã³ããã³ã¿ããžã³ããããªãŠã ã»ã¹ã©ãã³ãããªããã³ãããªã¡ãããªã åã³ããã°ã¢ãã«ã®ãããªæãã©ãªã¢è¬å€ã
é
ç³é
žã¢ã³ãã¢ã³ã«ãªãŠã ãããªããŸãŒã«ãã¢ã³ãã¢ã³ã»ãããªãŠã ã»ãžã¡ã«ã«ããã³ãã¯é
žããªããµã ããã³ãããã§ããŠã ãããã©ãžã³ããžã¯ãããã§ã³ããã©ãžã«ã³ãã«ããžãšãã«ã«ã«ãããžã³ããã©ã³ãã«ãã¢ãšãŒãããã«ã³ãã³ãããªããŠã ãã¢ãšãŒããã¬ãããŸãŒã«ãã¹ãã£ããã§ã³ãã¡ãã³ããŸãŒã«ãããã©ããŸãŒã«ãã¡ããªãããŒãããã¢ãã³ããŸãŒã«åã³ãã¯ããµããã®ãããªåè è«ç
è¬å€ã
ã¢ã¹ããªã³é
žãã¡ãã§ãã é
žãã¢ã¯ããã§ãã¯ãããããã»ã³ãã¢ãŸããããã³ãããã«ãã³é
žããã³ãžããã³ããªãã·ãã§ã³ãã¿ãŸã³ããžã¯ããã§ãã¯ããããã·ã«ã ããã§ããããã§ã³ããã«ãããã§ã³ããã«ã«ããããã§ã³ããµãªãã«é
žãããªãŠã ãã€ããããã§ã³ã¹ãªã³ããã¯ãã€ã³ãã¡ã¿ã·ã³ããã¢ãããã§ã³é
žãã±ããããã§ã³åã³ãã«ã¡ãã³ã®ãããªåççæ§è¬å€ã
ã³ã«ããã³åã³ã¢ãããªããŒã«ã®ãããªåç颚è¬å€ã
ã¢ã«ãã§ã³ã¿ãã«ãã¡ã¿ãã³ãããžãã©ãããã¢ã«ãããããã¬ãã«ãã£ã³ããã³ã¢ã«ãã£ã³ãããã«ãã§ããŒã«ããã³ã¿ãŸã·ã³ãã³ãã€ã³ããããžã³ãããã¹ããã¢ã©ãããããªãã©ãããããã¹ããããããã·ãã§ã³ãã¹ãã§ã³ã¿ãã«åã³ãã§ã³ã¿ãã«ã®ãããªäžæ¢äœçšïŒãªããªã€ãïŒé®çè¬ã
ã¢ã«ãã«ã€ã³ãã¡ããã«ã€ã³ããããã«ã€ã³ãããªãã«ã€ã³ããšããã«ã€ã³ãããã«ã€ã³ããªãã«ã€ã³åã³ããã©ã«ã€ã³ã®ãããªå±æç麻é
è¬ã
ã¢ãã³ããžã³ããžãã§ã³ããã©ãã³ãã¢ãã¢ã«ããããšãããããžã³ãã¡ã¿ã³ã¹ã«ãã³é
žãã³ãºãããã³ãã¬ã«ãŽããªã«ããããªãã³ãã¬ããããããã¢ã¯ãªããã³ããªã¹ãªããã«ã«ããããã¡ããã»ã³ãã¯ãã«ãã§ãããµãã³ããªã«ãã§ãããªã³ãã·ã¯ãªãã³ãããã·ã¯ãªãžã³ãããã»ãããåã³ããªããã·ãã§ããžã«ã®ãããªããŒãã³ãœã³ç
ã®ããã®è¬ã
ãã¯ããã§ã³ãã«ãªãœããããŒã«ãã¯ãã«ã¡ã¶ãã³ãã¯ãã«ãŸããµãŸã³ãã·ã¯ããã³ã¶ããªã³ããã³ããã¬ã³ããžã¢ãŒãã ããã§ãã«ãã¡ãŒããã¡ãã§ãããµãã³ãã¡ãã§ãã·ã³ãã¡ã¿ããµãã³ãã¡ãã«ã«ãã¢ãŒã«åã³ãã«ããªãŸã³ã®ãããªäžæ¢æ§çåŒç·©è¬ã
å¯è
ç®è³ªã¹ããã€ãã¯ä»¥äžãæããã
ã³ã«ããŸãŒã«ãããªãã·ã³ã«ãã³ã¹ããã³åã³ãã«ãªããããã³ã«ããŸã³ã®ãããªç¡æ©è³ªã³ã«ãã³ã¹ããã€ãã
ã³ã«ããŸãŒã«ãããªãã·ã³ã«ãã³ã¹ããã³åã³ãã«ãªããããã³ã«ããŸã³ã®ãããªç¡æ©è³ªã³ã«ãã³ã¹ããã€ãã
ãã¯ãã¡ã¿ãŸã³ããã¿ã¡ã¿ãŸã³ãã³ãŒããŸã³ããããµã¡ã¿ãŸã³ããã«ãªã·ããã³ããã«ãªã·ãããããã«ãªã³ã«ããã³ããã«ãªãã¡ããã³ããã«ãã¬ãããœãã³ããã«ã©ã³ãã¬ããªãããã«ã·ãããããããã³ã«ããŸã³ãã¡ããªãŸã³ãã¡ãã«ãã¬ãããŸãã³ããã©ã¡ã¿ãŸã³ããã¬ãããŸãã³ããã¬ãããŸã³åã³ããªã¢ã ã·ããã³ïŒã¢ã»ãããïŒã®ãããªå¯è
ç®è³ªã¹ããã€ãã
ã¢ã³ããã²ã³ã¯ä»¥äžãæãã
ãããŸãŒã«ããã«ãªãã·ã¡ã¹ããã³ãã¡ã¹ãããã³ãã¡ãã«ãã¹ãã¹ããã³ããã¹ãã¹ããã³åã³ãã®å¡©é¡ã®ãããªæ²»çã§äœ¿çšãããã¢ã³ããã²ããã¯ã¹ããã€ãã
ãããŸãŒã«ããã«ãªãã·ã¡ã¹ããã³ãã¡ã¹ãããã³ãã¡ãã«ãã¹ãã¹ããã³ããã¹ãã¹ããã³åã³ãã®å¡©é¡ã®ãããªæ²»çã§äœ¿çšãããã¢ã³ããã²ããã¯ã¹ããã€ãã
ã«ã«ã¹ããã³ããã³ãããã³åã³ãã®å¡©é¡ãããã¢ã¹ã¿ããã³ããªããµã³ãããã³ããšãã«ãšã¹ãã¬ããŒã«ããªãã·ã¡ããã³ãã¡ã¿ã³ããªãªãŒã«ãã¹ã¿ããŸããŒã«ã»ã¡ã¿ã¢ã³ããã¹ãããã³åã³ãã¹ãã©ã¯ãã³ã®ãããªæ²»çã§äœ¿çšãããçèå¢åŒ·å€ã
ã·ããããã³é
¢é
žå¡©ã®ãããªæã¢ã³ããã²ã³ã
ãžãšãã«ã¹ãã«ãã¹ãããŒã«ããšã¹ãã©ãžãªãŒã«ããšã¹ããªãªãŒã«ããšããã«ãšã¹ãã©ãžãªãŒã«ãã¡ã¹ãã©ããŒã«åã³ããã¹ãããŒã«ã®ãããªæ²»çã§äœ¿çšããããšã¹ããã²ã³ã»ã¹ããã€ããæãããšã¹ããã²ã³ã
ã¯ããããªã¢ãã»ã³ãã¯ãããã§ã³ããšã¿ã¢ãã·ããªãã§ããŒã«ãããã©ãã·ãžã³åã³ã¿ã¢ãã·ãã§ã³ã®ãããªæãšã¹ããã²ã³ã
ã¢ãªã«ãšã¹ãã¬ããŒã«ãããœã²ã¹ãã¬ã«ããžã¡ãã¹ããã³ããžããã²ã¹ããã³ããšããã«ãšã¹ãã¬ããŒã«ããšãã¹ããã³ããšãããžãªãŒã«ãžã¢ã»ããŒãããšãããžãªãŒã«ãããããã·ããã²ã¹ããã³ãã¬ããã«ã²ã¹ãã¬ã«ããªãã¹ãã¬ããŒã«ãã¡ãããã·ããã²ã¹ããã³ãã¡ã²ã¹ãããŒã«é
¢é
žå¡©ããã«ãšãã³ããã³ããã«ãšãã¹ããã³ããã«ãšãããã¬ã«ããã«ã²ã¹ãã¬ã«åã³ããã²ã¹ããã³ã®ãããªããã²ã¹ãã³ã
ç²ç¶è
ºè¬ã¯ä»¥äžãæããã
å·Šæãµã€ããã³åã³ãªãªãããã³ã®ãããªæ²»çã§äœ¿çšãããç²ç¶è ºè¬ãã«ã«ãããŸãŒã«ãã¡ãããŸãŒã«ãã¡ãã«ããªãŠã©ã·ã«åã³ãããã«ããªãŠã©ã·ã«ã®ãããªæ²»çã§äœ¿çšãããæç²ç¶è ºè¬ã
å·Šæãµã€ããã³åã³ãªãªãããã³ã®ãããªæ²»çã§äœ¿çšãããç²ç¶è ºè¬ãã«ã«ãããŸãŒã«ãã¡ãããŸãŒã«ãã¡ãã«ããªãŠã©ã·ã«åã³ãããã«ããªãŠã©ã·ã«ã®ãããªæ²»çã§äœ¿çšãããæç²ç¶è ºè¬ã
å
·äœäŸã«ãããšãçç©æŽ»æ§å€ã¯ãé 圱å€åã¯ã©ãã«ã®ãããªããŒã«ãŒç©è³ªã§ããã奜ãŸããã¯ãé 圱å€åã¯ã©ãã«ã¯ãçæ°Žæ§ãåã¯åŸ®ç²åç¹æ§ã§ããããããã®ã¿ã€ãã®è¬å€ã¯éåžžã«å¹ççã«çµã¿èŸŒãã倧éšåãå解ããããŸã§ãããªããŒãããªãã¯ã¹ãããªãªãŒã¹ãããªãã ãããç¹ã«é©ããŠããè¬å€ã¯ã液äœã®åœ¢åŒã®ãšãŒãåãããç·é 圱å€ã§ããããã®ç®çã®ããã«è£œåãšããªããŒã«ãäŸãã°äœ¿çšã§ããããã¯ãšãŒãåãããã±ã·æ²¹ã§ãããããé«ããšãŠçŽ è£
å¡«ã®ããã«ããšãŒãåãããæ²¹ã¯ãåæããããäŸãã°ãªã¯ã¿ã³âïŒâã€ã«ïŒïŒïŒïŒïŒâããªã»ãšãŒãã»ãã³ãŸã¢ãŒãã§ãããïŒïŒïŒïŒïœïœïŒïœïœããå€ããšãŠçŽ ã³ã³ãã³ããæã€ã
ããªããŒåŸ®ç²åã¯ãäžã€ä»¥äžã®çç©æŽ»æ§å€ãæããåã¯æ²»çè¬åã³é 圱å€ã®çµã¿åãããæããã氎溶æ§ã§ããçç©æŽ»æ§å€ã¯å¥ãšããŠãæãªãã·ãã³ããã€ãªã³ããã¬ãŒãå€ãææãã€ã¡ãŒãžã³ã°åæç©ã®ãããªä»ã®æ°Žæº¶æ§åæç©ãçµã¿èŸŒãŸãåŸãããŸããçæ°Žæ§çç掻æ§åæç©ã«å ããŠãä»ã®åæç©ããããªããŒã溶ããããã«çšãããã溶åªã«å ããããŠãããããããã®çæ°Žæ§åæç©ã¯ãæé
žåå€ãã€ãªã³ããã¬ãŒãå€ãææåã¯ã€ã¡ãŒãžã³ã°åæç©ã§ãããããäžèšã®ããã«ãæ¬çºæã®æ¹æ³åã³ããŒã«ã¯ãçæ°Žæ§åã³èŠªæ°Žæ§è¬å€å«æããªããŒåŸ®ç²åäž¡æ¹ãçæããããã«äœ¿çšã§ãããçæ°Žçãªè¬å€ã¯ãçŽæ¥ããªããŒæº¶æ¶²ã«çµã¿èŸŒãŸãã芪氎æ§è¬å€ã¯äºéä¹³å€æè¡ãä»ããŠçµã¿èŸŒãŸããã
æ¬çºæã®æ¬æ
æ§ã«ããæ¹æ³ã®ããã«ãäœããã®ã¿ã€ãã®çç©åŠçé©åæ§ã®ããªããŒã䜿çšã§ãããç¹å®ã®å®æœäŸã«ãããŠãçç©åŠçé©åæ§ã®ããªããŒããçå解æ§ã§ãããçå解æ§ã®çäœé©åæ§ããªããŒã®äŸã¯ãããªïŒã©ã¯ããïŒãããªïŒã°ãªã³ãªãïŒãããªïŒã©ã¯ããâïœïœâã°ãªã³ãªãïŒãããªã«ããã©ã¯ãã³ãããªã«ãŒãããŒããããªã¢ã¹ãã«ã¢ãããããªé
žç¡æ°Žç©ãããªïŒã¢ããé
žïŒãããªã»ãªã«ãã»ãšã¹ãã«é¡ãããªïŒãžã»ãªããµïŒãïŒãïŒãïŒïŒæã®ïŒæ¥ïŒãããªïŒã¢ã«ãã¬ã³ã»ã¢ã«ãã¬ãŒãïŒãããªã¢ã»ã¿ãŒã«ãããªã»ã·ã¢ãã¢ã¯ãªã¬ãŒããçç©å解å¯èœãªããªãŠã¬ã¿ã³é¡ãæ··ååã³ãã®å
±éåäœã§ãããéåžžã¯ãããªïŒã©ã¯ããïŒãæããããªããŒãã©ã¯ããåã³ã°ãªã³ãªãã®å
±éåäœããããã®ãã¬ã³ãåã¯ãããã®æ··åç©ã䜿çšããããæ¯æ§ãªããªããŒã¯ãåäžã®ç°æ§äœã¿ã€ãã®ã¢ãããŒåã¯ç°æ§äœã®æ··åç©ãã圢æã§ããã
çå解æ§ã§ãªãçäœé©åæ§ããªããŒã®äŸã¯ãããªã¢ã¯ãªã¬ãŒãããšãã¬ã³é
¢é
žããã«åã³ä»ã®ã¢ã·ã«çœ®æãããé
¢é
žã»ã«ããŒã¹ã®ããªããŒãé£å解æ§ããªãŠã¬ã¿ã³é¡ãããªã¹ãã¬ã³ãããªå¡©åããã«ãããåããªããã«ãããªïŒããã«ã»ã€ãããŸãŒã«ïŒãã¯ããã»ã¹ã«ãã³é
žå¡©ããªãªã¬ãã£ã³ãé
žåïŒïŒ°ïŒ¥ïŒ¯ïŒããªãšãã¬ã³ãæ··ååã³ãã®å
±éåäœã§ããã
ç¹å®ã®å®æœäŸã§ã¯ãããªããŒã¯ãâïŒããªä¹³é
žâé
žåããªãšãã¬ã³ïŒå
±éåäœã§ããã
æ¬çºæã®å¥ã®æ
æ§ã¯ãçç©æŽ»æ§å€ãæããïŒÎŒïœããïŒïŒïŒÎŒïœãç¹ã«ïŒÎŒïœããïŒïŒÎŒïœã®éã®ãµã€ãºãæã€ååæ£ããªããŒåŸ®ç²åããã€ã³ã¯ãžã§ããã䜿çšããŠèª¿è£œããæ¹æ³åã³ããŒã«ã«é¢ããããã§ããªããŒã¯ãããã²ã«ã§ããããããã²ã«ããªããŒã®äœ¿çšããããªããŒã®äœãæ¿åºŠããïŒïŒÎŒïœæªæºã®ç²åã®çæã蚱容ããããšãåãã£ãŠããŠãããã¯åã«é瀺ãããæè¡ïŒäŸãã°ïŒµïŒ³ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒãæã€èª²é¡ã§ãã£ãã液äœå
ã®ã€ã³ã¯ãžã§ãããããããªããŒç²åã®èšåŒµåã³ïŒåã¯ç¡¬åã®éãææ©æº¶å€ã¯ç²åããæ¡æ£ããäžæ¹ã§ã埮ç²åãžã®æ°Žã®åæ¡æ£ãããããããã²ã«ç²åã®åœ¢æã«ããããã®åæ¡æ£ã®æå©ãªçµæã¯ããŸã èªããããŠããªãã£ããæ°Žæ§åããæµäœãžã®ãããã²ã«æ¶²æ»Žã®æ³šå
¥ã®åŸã倧éã®æ°ŽããéèŠãªèšåŒµãžè³ããããã²ã«ç²åã«ããåžåãããããã®èšåŒµã¯ã液滎ãæ°Žæ§åããæµäœãšæ¥è§ŠããŠããæéããç¬ç«ããŠããã平衡å€ããã»ãŒå³åº§ã«åŸããããããºã«ããé¢ãããšã滎ã¯ãå°å å§ååã³åŽåºãããããªããŒã®éã«äŸåããŠãããºã«ã®çŽåŸãããããã«å€§ããçŽåŸãæã€ãå®éã«ã¯ãäŸãã°ïŒïŒãã¯ãã³ã®çŽåŸãæã€ããºã«ããåŽåºããããšã¯ãçŽïŒïŒÎŒïœã®çŽåŸãæã€æ¶²æ»Žãçæããããããã²ã«ç²åã®æçµçŽåŸã¯ãããªããŒäžã®æ°Žåå¯èœãªã°ã«ãŒãã®æ°ã«ãã決å®ããããããã²ã«ã®æ°Žåã®çšåºŠãšããªããŒæ¿åºŠãšã®çµåãã«äŸåããã ãããæ°Žã«ããè±æ°Žãããã²ã«ç²åã®ããªã¥ãŒã ã®è£åèšåŒµã¯ãæŠããŠãã¡ã¯ã¿ïŒãïŒã§ããããïŒãïŒãïŒåã¯ïŒïŒã®å€ãŸã§äžããããšãã§ããã
æŠããŠã溶åªã®é€å»ã®çµæãšããŠãïŒãïŒïŒ
ã®ããªããŒæ¿åºŠãæã€ïŒïŒÎŒïœã®çŽåŸãæã€åŽåºããããããã²ã«æ¶²æ»Žã¯ãæåã«ããã¡ã¯ã¿ïŒïŒïŒãïŒïŒã§ããªã¥ãŒã ãçž®å°ããçŽïŒïŒÎŒïœãïŒïŒÎŒïœã®çŽåŸãæã€ç²åãŸã§çŽåŸãçž®å°ãããæ°ŽåããŠããã¡ã¯ã¿ïŒã§ããªã¥ãŒã ãå¢å€§ãããšããæ¯æ§ãªç²åã¯ãçŽïŒïŒÎŒïœãïŒïŒÎŒïœã®çŽåŸãæã€ç²åã«ãµããããæ°Žåãããšãããã¡ã¯ã¿ïŒã§ããªã¥ãŒã ãå¢å€§ããç²åã¯ãããããçŽïŒïŒÎŒïœåã³ïŒïŒÎŒïœã®çŽåŸãæã€ç²åã«ãµããããçµæãšããŠçããæ°Žåãããããã²ã«ã»ããªããŒç²åã®ããã®ææã®ãµã€ãºã«åŸã£ãŠããªããŒã®ã¿ã€ãïŒããªãã¡æ°Žåã®çšåºŠïŒåã³ããªããŒæ¿åºŠãéžæããããšã¯ãåœæ¥è
ã®ç¯å²å
ã§ããã
ãã£ãŠããããã²ã«ããªããŒã¯ãèšåŒµããåŸã«ã¯æ¯èŒç倧ããªåŸ®ç²åãåŸãäžæ¹ã§ãæ¯èŒçå°ããªããªã¥ãŒã ãæã€ããªããŒæ¶²æ»ŽãåŽåºã§ãããšããå¹æãæã€ãããå°ããªæ¶²æ»Žã䜿çšããããšã«ããã液滎ããã®ãããã²ã«ã«ãã溶åªã®æ¡æ£ãèããå¢å€§ããããçµæãšããŠãããªããŒç²åã®èšåŒµåã³ïŒåã¯ç¡¬åã®ããã«å¿
èŠãšãããå
šäœã®æéã¯ãåçã«æžå°ããããããã«ãåããæµäœã溶åªã§æ±æãããªãã®ã§ãç²åãšåããæµäœãšã®éã®æº¶åªã®ããæ¥ãªåŸé
ããããªããŒç²åã®èšåŒµåã³ïŒåã¯ç¡¬åãä¿é²ããŠåã³ç¶æãããã
åŸã£ãŠãæ¬çºæã®å
·äœäŸã§ã¯ããããã²ã«ã»ããªããŒã®äœãæ¿åºŠãäŸãã°ïŒïŒïŒãïŒïŒ
ãç¹ã«ïŒïŒïŒïŒ
ã®ãããªä¹³å€ã®ãããã²ã«ã»ããªããŒã®ïŒïŒïŒãïŒïŒ
ãæã€ä¹³å€ã®äœ¿çšãæ³å®ããããä»ã®å
·äœäŸã«ãããŠãæ¯æ§ãªä¹³å€ã¯ãïŒÎŒïœãšïŒïŒïŒÎŒïœãšã®éãç¹ã«ïŒïŒÎŒïœãšïŒïŒÎŒïœãšã®éãæŽã«ç¹ã«ïŒïŒÎŒïœãšïŒïŒÎŒïœãšã®éã®çŽåŸãæã€ããºã«ããå°åºãããããããã²ã«ä¹³å€ã®ã€ã³ã¯ãžã§ããããã液滎ã®å¶åŸ¡ãããèšåŒµã¯ãããºã«çŽåŸã調ç¯ããããšã«ãããããºã«çŽåŸã®ïŒïŒãšïŒïŒïŒïŒ
ãšã®éã®çŽåŸãç¹ã«ã€ã³ã¯ãžã§ããããããã«äœ¿çšãããããºã«ã®çŽåŸã®ïŒïŒãïŒïŒïŒ
ãè¶
ããïŒç¹ã«ïŒïŒïŒ
ãïŒïŒïŒ
åã¯ïŒïŒïŒ
ãè¶
ããïŒçŽåŸãæã€åŸ®ç²åã®çæã蚱容ãããå
·äœäŸã§ã¯ãèšåŒµã®åŸåŸããããããã²ã«ç²åã®çŽåŸããããºã«ã®çŽåŸãšåãããã倧ããã§ããã
å®æœäŸã®ã»ã¯ã·ã§ã³ã¯ãïŒïŒÎŒïœã®çŽåŸãæã€ããºã«ããåŽåºããçŽïŒïŒ
ã®ãããã²ã«ã»ããªããŒæ¿åºŠããããºã«çŽåŸã®ïŒïŒïŒ
ã«å¯Ÿå¿ããçŽïŒïŒÎŒïœã®çŽåŸãæã€ããªããŒç²åãåŸãããã«äœ¿çšã§ããããšãå®èšŒããã
äžèšã®ããã«ã埮ç²åã®çç£ã®ãããããã²ã«åœ¢æããªããŒã®äœ¿çšã¯ãïŒïŒ
æªæºãåã¯æŽã«ïŒïŒ
æªæºã®ããªããŒæ¿åºŠãæã€ä¹³å€ã®äœ¿çšã蚱容ããããã¯äŒçµ±çã«äœ¿çšãããããªããŒæ¿åºŠããèããäœããæ¯æ§ãªä¹³å€ã¯ãããäœãç²æ§ãæã¡ãããã«ãããããäœãå§åãä¹³å€ãã€ã³ã¯ãžã§ããããã€ã¹ã«éãã®ã«å¿
èŠãªã ããªã®ã§ãã€ã³ã¯ãžã§ãããä¿é²ãããå ããŠããããã²ã«åœ¢æããªããŒã®äœ¿çšã¯ãã€ã³ã¯ãžã§ããã®éã«ããºã«æ±æãæžå°ããå¹æãæã€ã
ãã®ããã«ãæ¬çºæã¯ãçç©æŽ»æ§å€ãæããïŒÎŒïœãšïŒïŒÎŒïœãšã®éã®ç¯å²ã«ãããµã€ãºãæã€ãããã²ã«ã»ããªããŒåŸ®ç²åãçç£ããæ¹æ³ãäŸçµŠãããæ¬çºæã®æ¹æ³ã¯ãéåžžãçç©æŽ»æ§å€ãæãããäžèšã®ãããªãããã²ã«åœ¢æããªããŒã®ä¹³å€ã調補ããã¹ããããšãè£å©ã®å§åã䜿çšããæ¯åãä»äžããŠãæ°Žæ§åããæµäœã«æµžããããããºã«ããä¹³å€ã®æ¶²æ»ŽãæŸåºããã¹ããããšãæããã液滎ã溶åªã®é€å»åã³åèšæ»Žã®æ°Žãšã®é£œåã確å®ã«ããæéã®éãåããæµäœå
ã§åèšæ¶²æ»Žã移åã§ããããšã«ãããåèšæ¶²æ»Žã¯åŸ®ç²åã«ç¡¬åããããéåžžã¯ãïŒïŒïŒ
ãç¹ã«ïŒïŒïŒ
ãæŽã«ç¹ã«ïŒïŒïŒ
ãè¶
ãããæãç¹ã«ïŒïŒãšïŒïŒïŒ
以äžãšã®éã®æº¶åªããé€å»ãããæ°Žã«ãã£ãŠå
šãŠåã¯éšåçã«çœ®ãæãããããæ¬çºæã®æ¹æ³ã®å
·äœäŸã«ãããŠãç²åã¯ãæ¹æãªãã«åããæµäœå
ã移åããããæãç¹ã«ãç²åã¯ãæ¬é¡æ现æžã«èšèŒãããŠããããã«ç²åãåŸããé¢ã«ã¹ã©ã€ãã§ããããšã«ãããåããæµäœå
ã移åãããã
åŸã£ãŠãæ¬çºæã¯ãïŒÎŒïœãšïŒïŒïŒÎŒïœãšã®éã®çŽåŸãæŽã«ç¹ã«ïŒïŒÎŒïœãšïŒïŒÎŒïœãšã®éã®ç¯å²ã®çŽåŸãæãç¹ã«ïŒïŒÎŒïœãšïŒïŒÎŒïœãšã®éã®çŽåŸãæã€ããããã²ã«ããªããŒç²åã®ååæ£æ¯éå£ãäŸçµŠãããïŒïŒÎŒïœãšïŒïŒÎŒïœãšã®éã®ãµã€ãºãæã€ç²åã¯ãæãå°ããªè¡ç®¡ã®å¡æ ã®äœæã®ãããªå»ççšéã«ç¹ã«é©ããŠããã
å
·äœäŸã«ãããšããããã²ã«ã»ããªããŒåŸ®ç²åã¯ãäžã€ä»¥äžã®çç©æŽ»æ§å€ãæãããå
·äœäŸã«ãããŠããããã²ã«ç²åã¯ã芪氎æ§çç©æŽ»æ§å€ãæããããããã¯ãçç©æŽ»æ§å€ã¯çæ°Žæ§ã§ãããäºéä¹³å€æè¡ãäžèšã®éãã«äœ¿çšããããçç©æŽ»æ§å€ã®æ§è³ªã¯ã¯ãªãã£ã«ã«ã§ãªããæ³å®ãããçç©æŽ»æ§å€ã®é©åãªäŸã¯äžèšã®ããã«é瀺ãããã
ä»ã®å
·äœäŸã«ãããšããããã²ã«åŸ®ç²åã¯ã溶åªãžã®ã€ã³ã¯ãžã§ããã«ããäœãããããã«ããããããã²ã«åŸ®ç²åã¯ãäžèšã®ããã«ã段éçãªå€æŽåŸæãæã€åŸããé¢äžã«èœãšãããã
ããªããŒã®æ°Žæº¶æ§ã®é åã¯ããªããŒå
ã«æ··å
¥ãããç©è³ªãžã®æ°Žã®ã¢ã¯ã»ã¹ãå¯èœã«ããã®ã§ããããã²ã«ãç¹ã«èŠªæ°Žæ§ç©è³ªã®ãããã²ã«ã¯ãå¶åŸ¡éåºã®ããã«ç¹ã«æå¹ã§ããããªãªãŒã¹ã¯ãããªããŒå
ã®ç¹æ§åãµã€ãºã«äŸåããŠãå解åã®ããªããŒããã®ç©è³ªã®æ¡æ£ã«ãããåã³ïŒåã¯å解ããã«ã€ããŠããªããŒããã®ç©è³ªã®æ¡æ£ã«ããçºçããåœè©²ç¹æ§åãµã€ãºã¯æ¶æ©éã®ååéåã³æ¶æ©å¯åºŠã«ããå¶åŸ¡ããããæ··å
¥ãããç©è³ªã®é掻æ§åã¯ãã²ã«ã®åºå®åã³ä¿è·å¹æã®ããäœæžãããä»ã®åŸæŸæ§ã®ã·ã¹ãã ãšé¢é£ããç Žå±çãªççºå¹æãåé¿ããããããªããŒã®å解ã¯ãçµç«¯ã®ãšã¹ãã«çµåã®æŒžé²çãªå æ°Žå解ã«ãããçäœå
ã®éé¢ãã¯ãååã®æçµçãªåŸæŸã容æã«ãããæŠããŠããããã²ã«ã¯ãçå解æ§ã®éåå¯èœãªãæ žãæ žã®åå
端äžã®äŒžå±åã³å䌞å±äžã®ãšã³ããã£ãããå«ããã¯ãæ§é åäœãã圢æããããæ žã¯ã芪氎æ§ããªããŒåã¯ãªãªãŽãã§ãããå䌞å±ã¯ãçå解æ§ã®ãªãªãŽãã§ãããåãšã³ããã£ããã¯ããªãªãŽãã§ããäºéäœãåã¯ãã¯ããªæ§é åäœãšæ¶æ©çµåãã§ããã¢ãããŒã§ãããä»ã®å
·äœäŸã«ãããŠãæ žã¯çŽïŒïŒïŒãšïŒïŒïŒïŒïŒïŒïŒ€ïœãšã®éã®ååéã®èŠªæ°Žæ§ããªïŒãšãã¬ã³ã°ãªã³ãŒã«ïŒãªãªãŽããå«ã¿ãå䌞å±ã¯çŽïŒïŒïŒãšïŒïŒïŒïŒïŒ€ïœãšã®éã®ååéã®çå解æ§ã®ããªïŒÎ±ãŒããããã·é
žïŒãªãªãŽããå«ã¿ãåãšã³ããã£ããã¯ãæ¶æ©çµåã§ããå
±éåäœéã®éåã§ããçŽïŒïŒãšïŒïŒïŒïŒ€ïœãšã®éã®ååéã®ã¢ã¯ãªã«é
žå¡©ã¿ã€ãã»ã¢ãããŒåã¯ãªãªãŽãïŒããªãã¡ãççŽ âççŽ äºéçµåãå«ãïŒãå«ããä»ã®å®æœäŸã§ã¯ãçŽïŒïŒïŒïŒïŒïŒïŒ€ïœã®ååéã®ããªïŒãšãã¬ã³ã°ãªã³ãŒã«ïŒãªãªãŽããããªãæ žãçŽïŒïŒïŒïŒ€ïœã®ååéã®ããªïŒã°ãªã³ãŒã«é
žïŒãªãªãŽããããªã䌞å±ãåã³çŽïŒïŒïŒïŒ€ïœã®ååéã®ã¢ã¯ãªã«é
žå¡©éšåãããªããšã³ããã£ãããåãããã§ããã
æ žæ°Žæº¶æ§ã®é åãšããŠçšããããé©åãªç©è³ªã®äŸã¯ãããªïŒãšãã¬ã³ã°ãªã³ãŒã«ïŒãããªïŒé
žåãšãã¬ã³ïŒãããªïŒããã«ã¢ã«ã³ãŒã«ïŒãããªïŒããã«ãããªãã³ïŒãããªïŒãšãã«ãªããµãŸãªã³ïŒãããªïŒé
žåãšãã¬ã³ïŒã³ããªïŒãããã¬ã³ãªãã·ãïŒãããã¯ã³ããªããŒãå€ç³é¡åã¯ãã¢ã«ãã³é
žãããã¹ãã©ã³ãç¡«é
žãããªã³ãã³ã³ããã€ãã³ç¡«é
žããããªã³åã¯ã¢ã«ã®ã³é
žå¡©ã®ãããªçæ°Žåç©ãåã¯ãŒã©ãã³ãã³ã©ãŒã²ã³ãã¢ã«ããã³åã¯ãªãã«ããã³ã®ãããªã¿ã³ãã¯è³ªã§ããã
çå解æ§ã®é åã¯ããšã¹ãã«ããããããç¡æ°Žç©ããªã«ãã»ãšã¹ãã«åã³ãªã³é
žãšã¹ãã«çµåã®ãããªçç©å解æ§ã«åœ±é¿ãããããçµåã䜿çšããŠããã¢ãããŒåã¯ããªããŒããæ§æã§ããã
å æ°Žå解æ§ã§ããçå解æ§ã®æ§æèŠçŽ ã®äŸã¯ãã°ãªã³ãªããã©ã¯ãããεâã«ããã©ã¯ãã³ãä»ã®Î±ãŒããããã·é
žãåã³ç¡æ¯åã¯äœå
ã®éåžžã®ä»£è¬ç©è³ªãšããŠååšããç©è³ªãäœãä»ã®çç©åŠçã«å解å¯èœãªããªããŒã®ãªãªãŽãåã³ããªããŒã§ãããé©åãªããªïŒÎ±ãŒããããã·é
žïŒã¯ãããªïŒã°ãªã³ãŒã«é
žïŒãããªïŒïŒ€ïŒ¬âä¹³é
žïŒåã³ããªïŒïŒ¬âä¹³é
žïŒã§ãããä»ã®æçšãªç©è³ªã¯ãããªïŒã¢ããé
žïŒãããªïŒç¡æ°Žç©ïŒãããªïŒãªã«ãã»ãšã¹ãã«é¡ïŒåã³ããªïŒãªã³é
žãšã¹ãã«ïŒãå«ããããªïŒÎµâã«ããã©ã¯ãã³ïŒãããªïŒÎµïŒïŒã«ããã©ã¯ãã³ïŒãããªïŒÎŽâãã¬ãã©ã¯ãã³ïŒåã³ããªïŒÎ³âãããã©ã¯ãã³ïŒã®ãããªããªã©ã¯ãã³ãæå¹ã§ããã
ãã®äŸã¯ãâãªãªãŽã©ã¯ãã«âã¢ã¯ãªã«é
žå¡©ã§ãããæ¬é¡æ现æžã«ãããŠãããªïŒãšãã¬ã³ã°ãªã³ãŒã«ïŒåã¯ïŒ°ïŒ¥ïŒ§äžå¿æ§é åäœïŒæ žïŒã¯ãåªããçäœé©åæ§ã䌎ã£ãŠããã®é«ã芪氎æ§åã³æ°Žæº¶æ§ã«åºã¥ããŠæå¹ã§ãããããªã°ãªã³ãŒã«é
žã®ãããªçãããªïŒÎ±âããããã·é
žïŒã¯ããšã¹ãã«çµåã®å æ°Žå解ã«ããæ¥éã«ã°ãªã³ãŒã«é
žãç¡å®³ãªä»£è¬ç©è³ªãžå解ããã®ã§ãé©åãªé£é延é·ã§ãããæ¯æ§ãªãããã¯ãŒã¯ã¯ã氎溶æ§ã®è¬åã³é
µçŽ ãæ··å
¥ããŠãåäžã«åæ£ãããŠãããããå¶åŸ¡ãããã¬ãŒãã§å±ããããã«äœ¿çšã§ãããä»ã®é©åãªé£é延é·ã¯ãããªä¹³é
žãããªã«ããã©ã¯ãã³ãããªã»ãªã«ãã»ãšã¹ãã«é¡åã³ããªç¡æ°Žç©ã§ãããããªããããã䜿çšãããã
å
·äœäŸã«ãããŠããããã²ã«åŸ®ç²åã¯ãããªã»ã¢ã«ãã¬ã³ã»ã°ãªã³ãŒã«åã³è³éŠæã®ããªãšã¹ãã«ã®å
±éåäœãã調補ãããããã®å
±éåäœã¯ãå
±éåäœã®éã¿ã«åºã¥ããŠãçŽïŒïŒééïŒ
ããçŽïŒïŒééïŒ
ãç¹ã«ïŒïŒééïŒ
ãïŒïŒééïŒ
ãŸã§ã®ç¬¬äžæåãæããåœè©²ç¬¬äžæåã¯ãããªã»ã¢ã«ãã¬ã³ã»ã°ãªã³ãŒã«ãæããåŒâââââã®ãŠããããæã¡ãããã§ãã¯ããªïŒãªãã·ã»ã¢ã«ãã¬ã³ïŒã°ãªã³ãŒã«ããã®æ«ç«¯ããããã·ã«åºã®é€å»ã®åŸãæ®ã£ãŠããäºäŸ¡ææ©åºã§ãããã¯äºäŸ¡ææ©åºã§ãããå
±éåäœã®éã¿ã«åºã¥ããŠãçŽïŒééïŒ
ããçŽïŒïŒééïŒ
ãŸã§ã®ç¬¬ïŒã®æåãæããåœè©²ç¬¬ïŒã®æåã¯ãè³éŠæã®ããªãšã¹ãã«ã§ãããåŒâïŒââââââã®ãŠããããæã¡ãããã§ãã¯ïŒã€ããïŒã€ãŸã§ã®ççŽ ååãæã€çœ®æè¥ããã¯é眮æã¢ã«ãã¬ã³åã¯ãªãã·ã»ãžã¢ã«ãã¬ã³åºã§ãããã¯çœ®æåã¯é眮æäºäŸ¡è³éŠæã®åºã§ããã
äžã€ã®å®æœäŸã«ãããŠãããªã»ã¢ã«ãã¬ã³ã»ã°ãªã³ãŒã«ã¯ãããªãšãã¬ã³ã°ãªã³ãŒã«ãããªãããã¬ã³ã°ãªã³ãŒã«åã³ããªããã¬ã³ã»ã°ãªã³ãŒã«åã³ããããµããŒã®ãããªãããã®å
±éåäœããéžæããããäžã€ã®å®æœäŸã«ãããŠãããªã»ã¢ã«ãã¬ã³ã»ã°ãªã³ãŒã«ã¯ãããªãšãã¬ã³ã°ãªã³ãŒã«ã§ãããçšèªã¢ã«ãã¬ã³åã³ããªã»ã¢ã«ãã¬ã³ã¯ãæŠããŠç°æ§äœæ§é äœãæããããªãã¡ããããã¬ã³ã¯ïŒïŒïŒâãããã¬ã³åã³ïŒïŒïŒâãããã¬ã³äž¡æ¹ãæããããã¬ã³ã¯ïŒïŒïŒâããã¬ã³ãïŒïŒïŒâããã¬ã³ãïŒïŒïŒâããã¬ã³ãïŒïŒïŒâã€ãœããã¬ã³ãïŒïŒïŒâã€ãœããã¬ã³åã³ïŒïŒïŒâããã¬ã³ïŒããã©ã¡ãã¬ã³ïŒãæããããé«ãã¢ã«ãã¬ã³çžåç©ã«å¯ŸããŠãåæ§ã§ãããããªã»ã¢ã«ãã¬ã³ã»ã°ãªã³ãŒã«æåã¯ãå¿
èŠãªãã°çµåãããªãšã¹ãã«æåã«äŸçµŠããããã«ããžã«ã«ãã³é
žæ®åºââââã§çµäºããããã°ã«ãŒãã¯ããšåãå®çŸ©ãæã€è³éŠæåºã§ããããåã¯ãšãã¬ã³ããããã¬ã³ãããã¬ã³ãªã©ã®ãããªèèªæåºã§ãããã
ããªãšã¹ãã«æåã«ãããŠãäºäŸ¡ã®è³éŠæåºïŒ²ã¯ãã§ãã¬ã³ãããªãžã«ã»ãšã³ããããã«ã»ãšã³ãããã§ãã«ããªãã·ã»ãžãã§ãã«ãã¹ã«ãã»ãžãã§ãã«ãã¡ãã¬ã³ãžãã§ãã«ã§ãããæé«ïŒãŸã§ãªãã·ã§ã³ã§çœ®æãããç¹ã«æé«ïŒã€ãŸã§çœ®æåºãã¯ãããããããïŒâïŒã¢ã«ã³ãã·ãä»ã®ãã«ãªããããããã·ãïŒâïŒã¢ã«ãã«ããéžæããããéåžžã¯ãè³éŠæã®åºã®ïŒ²ã¯æªçœ®æã§ãããç¹ã«ãã¯ïŒãïŒâãã§ãã¬ã³ã§ãããããªãšã¹ãã«âââââââã®äŸã¯ãããªïŒãšãã¬ã³ã»ãã¬ãã¿ã«é
žå¡©ïŒãããªïŒãããã¬ã³ã»ãã¬ãã¿ã«é
žå¡©ïŒãããªïŒããã¬ã³ã»ãã¬ãã¿ã«é
žå¡©ïŒãããªïŒããã¬ã³ã»ã€ãœãã¿ã«é
žå¡©ïŒãããªïŒãšãã¬ã³ïŒïŒïŒÂŽâã¡ãã¬ã³ã»ãžãã§ãã«ã»ãžã«ã«ãã³é
žå¡©ïŒãããªïŒããã¬ã³ïŒïŒïŒïŒïŒïŒïŒâããã©ãããããã¿ã¬ã³âïŒïŒïŒâãžã«ã«ãã³é
žå¡©ïŒãªã©ãæããã
ç¹å®ã®å®æœäŸã§ã¯ãããªãšã¹ãã«ã¯ãããªãšãã¬ã³ã»ãã¬ãã¿ã«é
žå¡©ãããªãããã¬ã³ã»ãã¬ãã¿ã«é
žå¡©åã³ããªããã¬ã³ãã¬ãã¿ã¬ãŒãããéžæãããããã詳ããã¯ãããªãšã¹ãã«ã¯ãããªããã¬ã³ãã¬ãã¿ã¬ãŒãã§ããã
éåžžã«ç¹å®ã®å®æœäŸã«ãããŠãå
±éåäœã¯ãããªãšãã¬ã³ã°ãªã³ãŒã«ïŒããªããã¬ã³ãã¬ãã¿ã¬ãŒãã»ãããã¯ã³ããªããŒã§ãããããªã»ã¢ã«ãã¬ã³ã°ãªã³ãŒã«ã¯ãçŽïŒïŒïŒä¹è³çŽïŒïŒïŒïŒïŒïŒã®ååéãæã€ãããªïŒãªãã·ã»ãšãã¬ã³ïŒã°ãªã³ãŒã«ã®æ£ç¢ºãªååéã¯ããããªãã¯ã¹ã«ããå°å
¥ãããçç©åŠçã«æŽ»æ§ãªè¬å€ã®ã¿ã€ããå«ãæ§ã
ãªèŠå ã«äŸåããã
å
·äœäŸã«ãããŠããããã²ã«ã»ããªããŒã¯ãããªïŒé
žåãšãã¬ã³ïŒãã¬ãã¿ã«é
žå¡©åã³ããªïŒïŒïŒïŒâããã¬ã³ïŒãã¬ãã¿ã«é
žå¡©ïŒïŒ°ïŒ¥ïŒ§ïŒŽïŒïŒ°ïŒ¢ïŒŽïŒã®å
±éåäœã§ãããããã§ïŒ°ïŒ¥ïŒ§ïŒŽïŒïŒ°ïŒ¢ïŒŽã®ééæ¯çã¯ãïŒïŒïŒïŒïŒãè¶
ããŠïŒïŒïŒïŒïŒããïŒïŒïŒïŒïŒãŸã§ã®ç¯å²ã§ãããå
·äœäŸã«ãããŠãïŒïŒïŒïŒïŒã®åã³ïŒïŒïŒïŒïŒã®å
±éåäœã®ããªãšãã¬ã³ã»ã°ãªã³ãŒã«æåã¯ãïŒïŒïŒïŒïŒã®ååéãæã€ãä»ã®å
·äœäŸã«ãããŠãïŒïŒïŒïŒïŒã®å
±éåäœã¯ãïŒïŒïŒïŒïŒãïŒïŒïŒïŒïŒåã³ïŒïŒïŒïŒïŒã®ããããååéãæã€ããªãšãã¬ã³ã°ãªã³ãŒã«æ§æèŠçŽ ãæã€ã
ãããã²ã«åœ¢æããªããŒãã€ã³ã¯ãžã§ããããéã«äœ¿çšãããæ¬çºæã®æ¹æ³ã¯ãå®å®ãããæ·»å ç©ãå¿
èŠã§ãªããšããä»å çãªå¹æãæã€ãçå解æ§ã®ããªããŒã®åŸ®ç²åã®èª¿è£œã«ãããŠæŠããŠãæ·»å ç©ãå¿
èŠã§ããã䜿çšãããæãäžè¬ã®æ·»å ç©ã¯ãããªããã«ã¢ã«ã³ãŒã«ïŒïŒ°ïŒ¶ïŒ¡ïŒã§ãããããã¯ç°ãªãååéåã³ç°ãªãå æ°Žå解ã®çšåºŠã§åæ¥çã«å©çšå¯èœã§ãããã¯ãææ©æº¶å€å
ã®çå解æ§ã®ããªããŒã®æº¶æ¶²ãæ°Žãšæ··åããããšãã埮ç²åã調補ããéã®ïŒã€ã®æ©èœãæã€ã第ïŒã«ãã¯ãã€ã³ã¯ãžã§ããããåŸã«åœ¢æãããä¹³å€æ¶²æ»Žã®ããã®åªããå®å®å€ã§ããã第ïŒã«ãã¯ã硬åãã埮ç²åã®ããã®å®å®å€ãšããŠäœçšãã第ïŒã«ãã¯ãä¹³å€æ¶²æ»Žã®éã®åªæåã«å¯Ÿãã圱é¿ãæã€ã
æ¬çºæã®å
·äœäŸã®ãããã²ã«åœ¢æããªããŒã®äœ¿çšã¯ãä¹³å€æ¶²æ»Žå®å®æ§åã³åŸ®ç²åå®å®æ§ã«ã€ããŠã®ïŒ°ïŒ¶ïŒ¡ã®å®å®ãããäœçšã®å¿
èŠæ§ãåãé€ããåæ§ã«ãç²æ§ã匷åããŠããè¬å€ã¯ããã¯ã埮ç²åãµã€ãºãå¶åŸ¡ããããã«å¿
èŠã§ã¯ãªããæ¬çºæã«ãã氎溶液äžã®æµžããããŠåŽåºãå¶åŸ¡ãããèšåŒµã§ãåªæåã䜿çšããä¹³å€æ¶²æ»Žã®å解ãèµ·ãããåŸã£ãŠãããã»ã¹ã¯ãé£ç¶çžã«ä»å ã®ïŒ°ïŒ¶ïŒ¡ããªãå Žåã§ãè¡ãããåŸã£ãŠãå°ãªãæŽæµã¹ããããå¿
èŠãªã ãã§ãããåŸç¶ã®éãåŠçããããå¹ççãªå°å
¥ã«ã€ãªããåŸãã
æ¬çºæã®æ¹æ³ã¯ãæŽã«ããããã²ã«ããªãã䜿çšããããšãããã«ãããã¯ã®ãããªçé¢æŽ»æ§å€ã第ïŒã®ä¹³å€ã¹ãããããçç¥ã§ããäºéä¹³å€æè¡ã®äœ¿çšãå¯èœã«ããã
æ¬çºæã®ã€ã³ã¯ãžã§ããããæ¹æ³åã³ããŒã«ã«ãããŠãããªããŒä¹³å€ã®çç©æŽ»æ§å€ã¯ãã€ã³ã¯ãžã§ããã»ãããã®ãããªå§é»çŽ åãšçµã¿åãããããºã«ã䜿çšããè£å©ã®å§åã§æµäœïŒåããæµäœãšãåŒã°ããïŒã«å°å
¥ããããããºã«ã¯ã浞ããããŠã€ã³ã¯ãžã§ããããæ¢ç¥ã®æ¹æ³ã«ãããã£ãŠåããæµäœã«æµžæ°Žãããã
埮ç²åã®æµžããããã€ã³ã¯ãžã§ããã®ããã®ããã€ã¹ã¯ãäŸãã°ïŒ·ïŒ¯ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒåã³ïŒµïŒ³ïŒïŒïŒïŒïŒïŒïŒã«èšèŒãããŠããã
æ¯æ§ãªããã€ã¹ã¯ãããªããŒåã³çç©æŽ»æ§å€ã®ä¹³å€ïŒïŒïŒãä¿æããããã®ç¬¬ïŒã®ãªã¶ãŒãïŒïŒïŒãšãåããæµäœïŒïŒïŒãä¿æããããã®ç¬¬ïŒã®ãªã¶ãŒãïŒïŒïŒãšãåããæµäœã«ä¹³å€ãå°åºããããã®å°ãªããšãäžã€ã®ããºã«ïŒïŒïŒãæã€åŽåºã¢ãžã¥ãŒã«ãšãéåžžæããã
æ¬çºæã®ããã€ã¹ã«ãããŠãåããæµäœã®ããã®ç¬¬ïŒã®ãªã¶ãŒãïŒïŒïŒåã³ããºã«ïŒïŒïŒã¯ã第ïŒã®ãªã¶ãŒãïŒïŒïŒãåããæµäœã§æºããéãããºã«ïŒïŒïŒãåããæµäœã«æµžããããããã«é
ãããã
ããºã«ã®çŽåŸã¯ãåŸãããã¹ãç²åã®ãµã€ãºåã³ïŒåã¯çšããããããªããŒã®æ¿åºŠã«äŸåããŠèª¿æŽã§ããéåžžã¯ïŒÎŒïœããïŒïŒïŒÎŒïœã®éã«ãããå
·äœäŸã«ãããŠãæ¬çºæã®ããã€ã¹ã¯ãïŒïŒÎŒïœããïŒïŒÎŒïœã®éã®çŽåŸãæã€ããºã«ãæããã
äžã€ã®å®æœäŸã«ãããŠãããã€ã¹ã¯ãïŒïŒïŒïœïŒšïœâïŒããïŒïŒïŒïœïŒšïœâïŒã®ç¯å²ã®å°åºã¬ãŒãã§å°åºãå¶åŸ¡ããããã®å¶åŸ¡ã·ã¹ãã ãæãããä»ã®å®æœäŸã§ã¯ãå¶åŸ¡ã·ã¹ãã ã¯ããã«ã¹åãããæ§åŒã§ã®å°åºãåäœããããã«èª¿æŽãããç¹ã«å¶åŸ¡ã·ã¹ãã ã¯ããããã¯åœ¢åŒã®å±èµ·ãã«ã¹ãåŽåºã¢ãžã¥ãŒã«ã«ä»äžããããã«èšãããããä»ã®å®æœäŸã§ã¯ãåŽåºã·ã¹ãã ã¯å¹Ÿã€ãã®ããºã«ãå«ã¿ãå¶åŸ¡ã·ã¹ãã ã¯åå¥ã®ããºã«ã«å¯Ÿãã液滎ãµã€ãºã調æŽããããã«èšãããããä»ã®å®æœäŸã§ã¯ããªã¶ãŒãã¯ã枩床å¶åŸ¡ã·ã¹ãã ãå
·åããã
æ¬çºæã®æ¹æ³ã§é©çšã§ãã浞ããããŠã€ã³ã¯ãžã§ããããå
·äœäŸã¯ãïŒåè¿°ããïŒããŒããŒçïŒïŒïŒïŒïŒïŒã«èšèŒãããŠãããããã§ãïŒïŒÎŒïœãïŒïŒÎŒïœåã³ïŒïŒÎŒïœã®çŽåŸãæã€ããšãŸé§åãã€ã¯ãããããã€ã³ã¯ãžã§ããã»ããºã«ïŒïŒïŒ«âïŒïŒïŒïŒšïŒã䜿çšããŠãå®éšãè¡ããããå€éšãã«ã¹ãžã§ãã¬ãŒã¿ïŒFlukeïŒïŒïŒïŒïŒïŒããïŒïŒïœïŒšïœã®ç¯å²ã®åšæ³¢æ°ãåŸãããã«äœ¿çšãããããªãã·ã§ãã«ã®ãã€ã¯ããããããã©ã€ãïŒïŒïŒ€âïŒïŒïŒïŒšïŒãããã«ã¹ããªã¬ãŒãããç»åãæ®ãããšãå¯èœã«ãããããã圢æããã»ã¹ããã©ããŒãããããºã«ã¯ããªã¶ãŒãã®æ¶²äœå
ã«çœ®ããããã€ã³ã¯ãªã¶ãŒãã®éçæµäœå§ãå
åã§ãªãã£ãã®ã§ãäžå®å§åããããºã«ã®éå¡ãé²æ¢ããŠé«ã液滎圢æçãå¯èœã«ããããã«ä»äžããããå
žåçå§åã¯ãïŒïŒÎŒïœããºã«ã§ïŒïŒïŒããŒã«ãïŒïŒÎŒïœããºã«ã§ïŒïŒïŒããŒã«ãåã³ïŒïŒÎŒïœããºã«ã§ïŒïŒïŒããŒã«ã§ãããäžã€ã®å®æœäŸïŒå³ïŒã«å³ç€ºãããïŒã«ãããŠããªã¶ãŒãã¯åçŽå£ïŒãïŒãïŒã«ããåé¢ãããïŒã€ã®åºç»ãå«ã¿ãããã«ãã£ãŠãäžæ¹ã®åºç»ã¯ãä¹³å€æ¶²æ»Žã®æ確ãªã¢ã¬ã€ãåŸããããæ¯åæ°åã³å§åãã»ããããããã«çšããããããããéæããããšããããºã«ã¯ä¹³å€ã®çç£ã®ããã®åºç»ã§ãã第ïŒã®åºç»ã«çœ®ãããããºã«ãåŽåºãåã³æµžãç¶ãããïŒïŒååŸã«ãããºã«ã¯ç§»ããããã«ã¹ãžã§ãã¬ãŒã¿ããªãã«ããããããºã«ã¯æº¶æ¶²ããåãå€ãããäžæ¹ãå§åã¯ãŸã å°å ãããŠãããããºã«ãååãªç©ºæ°ã«ããåŸã«ã ããè£å©å§ããªãã«ããããããã¯ã氎溶液ãããºã«å
ã«æµå
¥ããªãããšã確å®ã«ããããã«ãªãããããåœè©²æµå
¥ã®å Žåã¯ç®è©°ãŸããåŒãèµ·ãããã€ã³ã¯ãžã§ããã®ããã€ã¹ã§ãäžè¿°ã®ããã«ã液滎ã¯ãçŽïŒïŒïŒïŒãïŒïŒïŒïŒïŒïŒïŒã®æ¶²æ»ŽïŒç§ã®ã¬ãŒãã§åŽåºããããéåžžã¯ãçç£çã¯ãç§åœããçŽïŒïŒïŒïŒïŒã§ããã
æ¬çºæã®äžã€ã®æ
æ§ã«ãããšãã€ã³ã¯ãžã§ããããåŸã埮ç²åã®ç¹å®ã®åŸåŠçãå¯èœã«ããããã€ã¹ãäŸçµŠããããæ¬çºæã®æ¬æ
æ§ã«ããããã€ã¹ã¯ãåããæµäœïŒïŒïŒãä¿æããããã®ç¬¬ïŒã®ãªã¶ãŒãïŒïŒïŒå
åã¯é£çµãããŠçœ®ãããåŸããé¢ïŒïŒïŒãæãããããºã«ïŒïŒïŒããæŸåºããã液滎ãåŸããé¢ïŒïŒïŒã®åŸæã®å§ãŸãã«æ¥è§Šåã¯çéžããããã«ãåŸããé¢ïŒïŒïŒã¯é
ããããäžèšã®ããã«ã圢æããã埮ç²åã¯ã極ããŠå£ããããã掻æ§åŸåŠçã«ãããäŸãã°åããæµäœã«åèšåŸ®ç²åãå
¥ããŠæ¹æããããšã«ããæå·ãåãããæ¬çºæã«ãããšã掻æ§åŸåŠçã延æåã¯çç¥ãããããã€ã¹ãäŸçµŠãããããã詳ããã¯ãããã€ã¹ã¯ãååçãªåŸåŠçã¹ãããã確å®ã«ããããã«ãããªãã¡æŸåºããã液滎ãåŸããé¢ïŒïŒïŒäžã®åããæµäœå
ã§ã¹ã©ã€ãã§ããããšã«ãããèšèšãããŠãããæãç¹ã«ãæ¬çºæã®ããã€ã¹ã¯åŸããé¢ãæããåœè©²åŸããé¢ã¯ãïŒïŒãïŒïŒåºŠãç¹ã«ïŒïŒããïŒïŒåºŠã®åŸæãæã€ãä»ã®å®æœäŸã«ãããšãæ¬çºæã®ããã€ã¹ã¯ãåçŽã«å§ãŸã£ãŠãïŒïŒãïŒïŒåºŠã®éã®è§åºŠã§çµãã段éçãªå€æŽåŸæãæãããæ¬çºæã®å
·äœäŸã«ããããã€ã¹ã®äŸã¯ãå³ïŒåã³å³ïŒã«æäŸãããã
æ¬çºæã®æ¹æ³åã³ããã€ã¹ã¯ãååæ£ã§ãããããªãã¡éåžžã«çããµã€ãºååžãæã€åŸ®ç²åã®æ¯éå£ã®çæãå¯èœã«ããããã®ããã«ãæ¬çºæã®ä»ã®æ
æ§ã¯ãïŒÎŒïœããïŒïŒïŒÎŒïœãç¹ã«ïŒÎŒïœããïŒïŒÎŒïœãç¹ã«ïŒïŒÎŒïœããïŒïŒÎŒïœãããã«ç¹ã«ïŒïŒÎŒïœããïŒïŒÎŒïœã®çŽåŸãæã€ååæ£åŸ®ç²åã®æ¯éå£ã«é¢ãããæ¯æ§ãªæ¯éå£å
ã§ã¯ãïŒïŒïŒ
ãè¶
ãã埮ç²åã¯ãåèšæ¯éå£ã®å¹³åå€ã®ïŒïŒïŒÎŒïœã«å
¥ãçŽåŸãæã€ãå
·äœäŸã«ãããŠãæãç¹ã«ãããã²ã«ã»ããªããŒãçšããããæã§ãæ¯éå£ã¯ãïŒïŒïŒ
ãè¶
ãã埮ç²åãæ¯éå£ã®å¹³åå€ã®ïŒïŒïŒÎŒïœã«å
¥ãçŽåŸãæã€ãšããäºå®ã«ããç¹åŸŽã¥ãããããå
·äœäŸã«ãããŠãæ¯æ§ãªæ¯éå£å
ã§ã¯ãïŒïŒïŒ
ãè¶
ãã埮ç²åã¯ãå¹³åçŽåŸã®ïŒïŒ
ã«å
¥ãçŽåŸãæã€ãå
·äœäŸã«ãããšã埮ç²åã¯ããããã²ã«ã»ããªããŒåŸ®ç²åã§ãããä»ã®å®æœäŸã«ãããšã埮ç²åã¯ãçç©æŽ»æ§å€ãå«ããä»ã®å®æœäŸã«ãããšã埮ç²åã¯ã芪氎æ§çç©æŽ»æ§å€ãå«ãã
åæã®èšåŒµåã³ïŒåã¯ç¡¬åã®éã埮ç²åãåŸããé¢ã転ãããåã¯ã¹ã©ã€ãããæ¬çºæã®æ¹æ³ã¯ãæ¹æããéãæããã埮ç²åã®è¡çªäžã«èµ·ãããããªç²åãžã®æå·ãé²æ¢ããããã®åŸ®åŠãªåŠçã¯ãæ¬çºæã®æ¹æ³ã«ããåŸããããããªåŸ®ç²åã®å
šäœã®åœ¢ç¶äžã®æçãªå¹æãæã¡ãç¹ã«åœè©²æ¹æ³ã¯ãç²åã®å
šäœã®çç¶åœ¢ç¶åã³ïŒåã¯æ»ãããªïŒãžããã§ããªãïŒè¡šé¢ãåŸãããã«æå©ã§ãããåŸã£ãŠãæ¬çºæã¯ãæ¯éå£ã®ç²åã®ïŒïŒ
æªæºãç¹ã«ïŒïŒ
æªæºåã¯æãç¹ã«ïŒïŒ
æªæºã ãããå
šäœã®çç¶åœ¢ç¶ããéžè±ãïŒïŒïŒïŒ
ãè¶
ããç¹ã«ïŒïŒ
ãè¶
ããŠéžè±ïŒåã³ïŒåã¯ããŒã¿ãæã¡ãåã³ïŒåã¯ä»ã®ã¿ã€ãã®æå·é¢ãæã€åœ¢ç¶ãæã€åŸ®ç²åæ¯éå£ã®çç£ãå¯èœã«ããã
æ¬çºæã®ä»ã®æ
æ§ã¯ãçç掻æ§ã®è¬å€ã®åºä¹³é¡ãžã®æäžã«å¯Ÿããæ¬çºæã®åŸ®ç²åã®äœ¿çšã«é¢ããã
æ¬çºæã®åŸ®ç²åã¯ãå€çš®å€æ§ãªå»ççšéã«é©çšã§ããã埮ç²åã¯ãç®äžç®¡çãéèå
æäžãåèå
管çãè
¹èå
管ççèå
管çãè£å
æäžåã³çŽè
žç®¡çã®ãããªéçµå£åã³ç²è管çïŒäŸãã°çµå£æäžïŒã®ããã®å»è¬åçµæç©ã«çµã¿èŸŒãŸãåŸãã
æ¬çºæã®åŸ®ç²åã®åªããç¹æ§ã¯ãã¢ããªã±ãŒã·ã§ã³ã«ãã£ãŠã¯åŸ®ç²åã®ãµã€ãºãã¯ãªãã£ã«ã«ã§ããåœè©²ã¢ããªã±ãŒã·ã§ã³ã«åŸ®ç²åããæãŸãããªãå¹æãåé¿ããããã«ãç¹ã«é©ããŠããããã«ãããããã¯ãäŸãã°ãåå®®ãã£ããã€ãã®æ²»çã«ãããŠãäŸãã°å¡æ 圢æçæ³ã®å Žåã§ãããä»ã®å¿çšã¯ãçç©æŽ»æ§å€ã®åŸæŸãæãã埮ç²åãå°å
¥ããã埮ç²åã®ãµã€ãºãããåäžã§ãããšããäºå®ã®çµæãšããŠããæ£ç¢ºã«éåºãããã
ãã£ãŠãæ¬çºæã¯ããã®ããŒãºã®æ£è
ã«å¯Ÿããæ²»ççãªåæç©ã§ããçç©æŽ»æ§å€ãæããæ¬çºæã®åŸ®ç²åãæäžããã¹ããããæããåŠçã®æ¹æ³ã«é¢ãããå ããŠãæ¬çºæã¯ã蚺æãããã¹ãæ£è
ã«å¯Ÿããé 圱å€åã¯ããŒã«ãŒã§ããçç©æŽ»æ§å€ãæããæ¬çºæã®åŸ®ç²åãæäžããã¹ããããæãã蚺æã®æ¹æ³ã«é¢ããã
æ¬çºæãå®æœããã·ã¹ãã åã³æ¹æ³ã®ä»ã®è£
眮ã¯ãåœæ¥è
ã«ãšã£ãŠæããã ããã
奜ãŸããå®æœäŸãç¹å®ã®æ§æåã³ç©è³ªã ãã§ãªãé
眮æ§æãæ¬çºæã«ããããã€ã¹ã®ããã«æ¬é¡æ现æžã«ãããŠè¿°ã¹ãããã«ããããããã圢ç¶ã®ããŸããŸãªå€ååã¯ä¿®æ£åã³çŽ°éšãæ¬çºæã®ç¯å²åã³è¶£æšãéžè±ããªãç¯å²ã§ãªãããŠãããããšãç解ãã¹ãã§ããã
äŸïŒïŒå€åæ¯åæ°ãæã€ïŒïŒÎŒïœã®ããºã«ããã®ïŒ°ïŒ¥ïŒ§ïŒŽïŒïŒ°ïŒ¢ïŒŽå
±éåäœä¹³å€ã®æ³šå
¥
ïŒïŒ ã®ïŒ°ïŒ¥ïŒ§ïŒŽâ溶液ã¯ã浞ãããããã€ã¯ãããããããºã«ã§ïŒïŒïŒïŒ ã®ïœïœïœïŒïŒïŒïŒãæãã氎溶液ã«ã€ã³ã¯ãžã§ããããããïŒïŒÎŒïœã®ããºã«ããçšãããããïŒïŒïŒããŒã«ã®å§å䞊ã³ã«ïŒïŒïŒïŒãïŒïŒãïŒïŒåã³ïŒïŒïœïŒšïœã®æ¯åæ°ã§ïŒïŒåéãã€ã³ã¯ãžã§ãããå®è¡ããããåèšæ°Žæº¶æ¶²ã«ãããŠåŸããé¢ã¯æµžãããã液滎ã¯ããã®æµžããããé¢ãä»ããŠä»ã®å®¹åšãžè»¢ãããåã¯ã¹ã©ã€ãããããšã«ãã移åã§ãããããã§ã埮ç²åã¯å®çããããã«æ®ããäžæŸã¿ãåãé€ããã容åšã¯æ°Žã§åã³æºãããããæ°Žæ§çžãžã®æº¶è§£ã«ãããžã¯ãããšã¿ã³ãåãé€ãããã«ïŒâïŒæéæ¹æããåŸã«ã埮ç²åã¯ãïŒïŒÎŒïœã®éå£éšã䜿çšããŠã¯ãŒã«ã¿ãŒã»ãã«ããµã€ã¶ãŒïŒ©ïŒ©ïŒ©ã§æž¬å®ããããããªã¥ãŒã å éåã³æ°å éäž¡æ¹ã®æ§åŒã®çŽåŸã¯ãïŒïŒïŒïŒïŒÎŒïœãïŒïŒïŒïŒïŒÎŒïœãïŒïŒïŒïŒïŒÎŒïœåã³ïŒïŒïŒïŒïŒÎŒïœã§ãã£ããããªã¥ãŒã å éå¹³åçŽåŸã¯ãïŒïŒïŒïŒïŒÎŒïœãïŒïŒïŒïŒïŒÎŒïœãïŒïŒïŒïŒïŒÎŒïœåã³ïŒïŒïŒïŒïŒÎŒïœã§ãã£ãããµã€ãºååžã¯ãå³ïŒã§äžãããããããŒã¯ã®å¹ ã¯ãïŒïŒïŒ ãè¶ ããç²åïŒïŒïŒâïŒïŒãã¯ãã³ã®éã§ã¯ãŒã«ã¿ãŒã»ã«ãŠã³ã¿ã®ãã¹ãŠã®ã«ãŠã³ããèæ ®ããïŒããå¹³åå€ã®ïŒïŒïŒÎŒïœä»¥å ã«ããããšã瀺ãã
ïŒïŒ ã®ïŒ°ïŒ¥ïŒ§ïŒŽâ溶液ã¯ã浞ãããããã€ã¯ãããããããºã«ã§ïŒïŒïŒïŒ ã®ïœïœïœïŒïŒïŒïŒãæãã氎溶液ã«ã€ã³ã¯ãžã§ããããããïŒïŒÎŒïœã®ããºã«ããçšãããããïŒïŒïŒããŒã«ã®å§å䞊ã³ã«ïŒïŒïŒïŒãïŒïŒãïŒïŒåã³ïŒïŒïœïŒšïœã®æ¯åæ°ã§ïŒïŒåéãã€ã³ã¯ãžã§ãããå®è¡ããããåèšæ°Žæº¶æ¶²ã«ãããŠåŸããé¢ã¯æµžãããã液滎ã¯ããã®æµžããããé¢ãä»ããŠä»ã®å®¹åšãžè»¢ãããåã¯ã¹ã©ã€ãããããšã«ãã移åã§ãããããã§ã埮ç²åã¯å®çããããã«æ®ããäžæŸã¿ãåãé€ããã容åšã¯æ°Žã§åã³æºãããããæ°Žæ§çžãžã®æº¶è§£ã«ãããžã¯ãããšã¿ã³ãåãé€ãããã«ïŒâïŒæéæ¹æããåŸã«ã埮ç²åã¯ãïŒïŒÎŒïœã®éå£éšã䜿çšããŠã¯ãŒã«ã¿ãŒã»ãã«ããµã€ã¶ãŒïŒ©ïŒ©ïŒ©ã§æž¬å®ããããããªã¥ãŒã å éåã³æ°å éäž¡æ¹ã®æ§åŒã®çŽåŸã¯ãïŒïŒïŒïŒïŒÎŒïœãïŒïŒïŒïŒïŒÎŒïœãïŒïŒïŒïŒïŒÎŒïœåã³ïŒïŒïŒïŒïŒÎŒïœã§ãã£ããããªã¥ãŒã å éå¹³åçŽåŸã¯ãïŒïŒïŒïŒïŒÎŒïœãïŒïŒïŒïŒïŒÎŒïœãïŒïŒïŒïŒïŒÎŒïœåã³ïŒïŒïŒïŒïŒÎŒïœã§ãã£ãããµã€ãºååžã¯ãå³ïŒã§äžãããããããŒã¯ã®å¹ ã¯ãïŒïŒïŒ ãè¶ ããç²åïŒïŒïŒâïŒïŒãã¯ãã³ã®éã§ã¯ãŒã«ã¿ãŒã»ã«ãŠã³ã¿ã®ãã¹ãŠã®ã«ãŠã³ããèæ ®ããïŒããå¹³åå€ã®ïŒïŒïŒÎŒïœä»¥å ã«ããããšã瀺ãã
äŸïŒïŒïŒ°ïŒ¥ïŒ§ïŒŽïŒïŒ°ïŒ¢ïŒŽå
±éåäœåä¹³å€ã®æ³šå
¥
ïŒïŒ ã®æ°Žãããžã¯ããã¡ã¿ã³ã®ïŒïŒ ã®ïŒ°ïŒ¥ïŒ§âã®æº¶æ¶²ã«å ãããããæ··åç©ã¯ïŒïŒç§éã®ïŒµïœïœïœïœïœïœïœïœïœïœïŒç»é²åæšïŒã䜿çšããŠä¹³ç¶ã«ããã匷ãæ£åšããä¹³å€ãçããããã®ä¹³å€ã¯ãïŒïŒïŒïŒïœïŒšïœã®æ¯åæ°åã³ïŒïŒïŒïŒããŒã«ã®è£å©å§åã§ã第ïŒã®å®¹åšã®ïŒïŒïŒïŒïŒ ïœïœïœãæãã氎溶液ãžæµžããããïŒïŒÎŒïœã®ããºã«ã䜿çšããŠãã€ã³ã¯ãžã§ããããããäŸïŒã§èª¬æããããã«ã液滎ã¯ã第ïŒã®å®¹åšã®æµžããããåŸããé¢äžãžæ°Žæº¶æ¶²ã«åŽåºãããã液滎ã¯ãå®çããããã«æ®ã第ïŒã®å®¹åšãžåŸæãåŸã ã«è»¢ãããã¹ã©ã€ããããäžæŸã¿ã¯åãé€ããã第ïŒã®å®¹åšã¯æ°Žã§åã³æºãããããæ°Žæ§çžãžã®æº¶è§£ã«ãããžã¯ããã¡ã¿ã³ãé€å»ããããã«ïŒâïŒæéæ¹æããåŸã埮ç²åã¯ãïŒïŒÎŒïœã®éå£éšã䜿çšããŠã¯ãŒã«ã¿ãŒã»ãã«ããµã€ã¶ãŒïŒ©ïŒ©ïŒ©ã§æž¬å®ããããåºæºãµã³ãã«ããåãå§åãæ¯åæ°åã³åããæµäœã䜿çšããŠïŒïŒ ã®ïŒ°ïŒ¥ïŒ§â溶液ãã調補ããããäž¡æ¹ã®ãµã³ãã«ã®ãµã€ãºååžã¯ãå³ïŒã§äžããããçµæãšããŠçããç²åã®ïŒ³ïŒ¥ïŒç»åã¯å³ïŒã§äžãããããåä¹³å€åã³åºæºç²åäž¡æ¹ã«å¯ŸããŠãïŒïŒïŒ ãè¶ ããç²åããæ°ã®å¹³ååãããçŽåŸã®ïŒïŒ 以å ã«ããã
ïŒïŒ ã®æ°Žãããžã¯ããã¡ã¿ã³ã®ïŒïŒ ã®ïŒ°ïŒ¥ïŒ§âã®æº¶æ¶²ã«å ãããããæ··åç©ã¯ïŒïŒç§éã®ïŒµïœïœïœïœïœïœïœïœïœïœïŒç»é²åæšïŒã䜿çšããŠä¹³ç¶ã«ããã匷ãæ£åšããä¹³å€ãçããããã®ä¹³å€ã¯ãïŒïŒïŒïŒïœïŒšïœã®æ¯åæ°åã³ïŒïŒïŒïŒããŒã«ã®è£å©å§åã§ã第ïŒã®å®¹åšã®ïŒïŒïŒïŒïŒ ïœïœïœãæãã氎溶液ãžæµžããããïŒïŒÎŒïœã®ããºã«ã䜿çšããŠãã€ã³ã¯ãžã§ããããããäŸïŒã§èª¬æããããã«ã液滎ã¯ã第ïŒã®å®¹åšã®æµžããããåŸããé¢äžãžæ°Žæº¶æ¶²ã«åŽåºãããã液滎ã¯ãå®çããããã«æ®ã第ïŒã®å®¹åšãžåŸæãåŸã ã«è»¢ãããã¹ã©ã€ããããäžæŸã¿ã¯åãé€ããã第ïŒã®å®¹åšã¯æ°Žã§åã³æºãããããæ°Žæ§çžãžã®æº¶è§£ã«ãããžã¯ããã¡ã¿ã³ãé€å»ããããã«ïŒâïŒæéæ¹æããåŸã埮ç²åã¯ãïŒïŒÎŒïœã®éå£éšã䜿çšããŠã¯ãŒã«ã¿ãŒã»ãã«ããµã€ã¶ãŒïŒ©ïŒ©ïŒ©ã§æž¬å®ããããåºæºãµã³ãã«ããåãå§åãæ¯åæ°åã³åããæµäœã䜿çšããŠïŒïŒ ã®ïŒ°ïŒ¥ïŒ§â溶液ãã調補ããããäž¡æ¹ã®ãµã³ãã«ã®ãµã€ãºååžã¯ãå³ïŒã§äžããããçµæãšããŠçããç²åã®ïŒ³ïŒ¥ïŒç»åã¯å³ïŒã§äžãããããåä¹³å€åã³åºæºç²åäž¡æ¹ã«å¯ŸããŠãïŒïŒïŒ ãè¶ ããç²åããæ°ã®å¹³ååãããçŽåŸã®ïŒïŒ 以å ã«ããã
äŸïŒïŒïŒ°ïŒ¥ïŒ§ïŒŽâã®ããã«ä¹³å€ã®ã€ã³ã¯ãžã§ããïŒèå
ã¿ã³ãã¯è³ªã®çµèŸŒã¿
äŸïŒã®èª¿è£œã¯ãèå ã¿ã³ãã¯è³ªã®çµèŸŒã¿ã§ç¹°ãè¿ããããã¿ã³ãã¯è³ªïŒã·ã°ãâãªãŒã«ããªããã®èå ååéæšæºïŒŠïŒïŒïŒïŒïŒã®ïŒŠïŒ©ïŒŽïŒ£å€æŽãããæ··åç©ãçšãããããã¿ã³ãã¯è³ªæ··åç©ãå«ãïŒïŒ ã®æ°Žãããžã¯ããã¡ã¿ã³ã®ïŒïŒ ã®ïŒ°ïŒ¥ïŒ§ïŒŽâ溶液ã«å ãããããã€ã³ã¯ãžã§ããã®çŽåŸã«ãç²åãçž®å°ããããšããé¡åŸ®é¡äžã§ãã©ããŒãããå³ïŒã«ç€ºãããããã«ãæçµçãªãµã€ãºã«å°éãããããšãç»åãæ®ãããã
äŸïŒã®èª¿è£œã¯ãèå ã¿ã³ãã¯è³ªã®çµèŸŒã¿ã§ç¹°ãè¿ããããã¿ã³ãã¯è³ªïŒã·ã°ãâãªãŒã«ããªããã®èå ååéæšæºïŒŠïŒïŒïŒïŒïŒã®ïŒŠïŒ©ïŒŽïŒ£å€æŽãããæ··åç©ãçšãããããã¿ã³ãã¯è³ªæ··åç©ãå«ãïŒïŒ ã®æ°Žãããžã¯ããã¡ã¿ã³ã®ïŒïŒ ã®ïŒ°ïŒ¥ïŒ§ïŒŽâ溶液ã«å ãããããã€ã³ã¯ãžã§ããã®çŽåŸã«ãç²åãçž®å°ããããšããé¡åŸ®é¡äžã§ãã©ããŒãããå³ïŒã«ç€ºãããããã«ãæçµçãªãµã€ãºã«å°éãããããšãç»åãæ®ãããã
äŸïŒïŒä»å ã®å®å®å€ããªãã€ã³ã¯ãžã§ãã
ä»å ã®å®å®å€ãªãã®ã€ã³ã¯ãžã§ãããžã¯ããã¡ã¿ã³ã®ïŒïŒ ã®ïŒ°ïŒ¥ïŒ§ïŒŽâ溶液ããïŒïŒïŒïŒïœïŒšïœã®æ¯åæ°åã³ïŒïŒïŒïŒããŒã«ã®è£å©å§åã§ä»ã®æ·»å ç©ãªãã«æ°ŽãžæµžããããïŒïŒÎŒïœã®ããºã«ã䜿çšããŠã€ã³ã¯ãžã§ããããããæŽæµåŸããµã³ãã«ã¯ãå³ïŒã«ç€ºãããããã«ïŒ³ïŒ¥ïŒåçã§æ®ãããã
ä»å ã®å®å®å€ãªãã®ã€ã³ã¯ãžã§ãããžã¯ããã¡ã¿ã³ã®ïŒïŒ ã®ïŒ°ïŒ¥ïŒ§ïŒŽâ溶液ããïŒïŒïŒïŒïœïŒšïœã®æ¯åæ°åã³ïŒïŒïŒïŒããŒã«ã®è£å©å§åã§ä»ã®æ·»å ç©ãªãã«æ°ŽãžæµžããããïŒïŒÎŒïœã®ããºã«ã䜿çšããŠã€ã³ã¯ãžã§ããããããæŽæµåŸããµã³ãã«ã¯ãå³ïŒã«ç€ºãããããã«ïŒ³ïŒ¥ïŒåçã§æ®ãããã
äŸïŒïŒïœïœïœïœåã³ïœïœïœâïœïœ
ïœãã€ã³ã¯ãžã§ãã
ïŒïŒïŒïŒïŒ ã®ïœïœïœâïœïœ ïœåã³ïŒïŒïŒïŒïŒ ã®ïœïœïœïœãå«ã溶液ïŒïŒ¡ïŒã¯ãïŒïŒåéã«ïŒïŒïœïŒšïœã®æ¯åæ°ã§æ°Žæ§ïŒïŒïŒïŒ ïœïœïœæº¶æ¶²ã«ïŒïŒãã¯ãã³ã»ããºã«ã䜿çšããŠã€ã³ã¯ãžã§ããããããã€ã³ã¯ãžã§ããåŸãçç£ç©ã¯ïŒåºŠæŽæµãããæ®ç溶åªãèžçºãããããã«æ¹æãããŠæ®ããããµã€ãºååžããå³ïŒã«ç€ºãããã
ïŒïŒïŒïŒïŒ ã®ïœïœïœâïœïœ ïœåã³ïŒïŒïŒïŒïŒ ã®ïœïœïœïœãå«ã溶液ïŒïŒ¡ïŒã¯ãïŒïŒåéã«ïŒïŒïœïŒšïœã®æ¯åæ°ã§æ°Žæ§ïŒïŒïŒïŒ ïœïœïœæº¶æ¶²ã«ïŒïŒãã¯ãã³ã»ããºã«ã䜿çšããŠã€ã³ã¯ãžã§ããããããã€ã³ã¯ãžã§ããåŸãçç£ç©ã¯ïŒåºŠæŽæµãããæ®ç溶åªãèžçºãããããã«æ¹æãããŠæ®ããããµã€ãºååžããå³ïŒã«ç€ºãããã
溶液ïŒïŒ¡ïŒã«ïŒïŒ
ã®çé¢æŽ»æ§å€ãã«ãããã¯ïŒŠïŒïŒïŒãå«ãïŒïŒïŒïŒ
ã®æ°Žãå ããããä¹³å€ã¯è¶
é³æ³¢ãä»äžããããšã«ãã調補ããããããã¯ãããªããŒæº¶æ¶²ã®æ°Žæ»Žã®åŒ·ãæ£åšããä¹³å€ã«è³ã£ããåèšä¹³å€ã¯ãïŒïŒåéãïŒïŒïœïŒšïœã®æ¯åæ°ã§æ°Žæ§ïŒïŒïŒïŒ
ïœïœïœæº¶æ¶²ã®ïŒïŒãã¯ãã³ã»ããºã«ã䜿çšããŠã€ã³ã¯ãžã§ããããããã€ã³ã¯ãžã§ããåŸãçç£ç©ã¯ïŒåºŠæŽæµãããæ®ç溶åªãèžçºãããããã«æ¹æããŠæ®ãããããµã€ãºååžããå³ïŒã«ç€ºãããã
äŸïŒïŒã«ãã»ã«ãå«ããšãŒãåããã液äœã®èª¿è£œã
ïŒïŒãã¯ãã³çäœãå«ããªã¯ã¿ã³âïŒâã€ã«ïŒïŒïŒïŒïŒâããªã»ãšãŒãã»ãã³ãŸã¢ãŒãã¯ãïŒïŒïœïŒšïœã®é床ã§ïŒïŒïŒïŒ ã®ïœïœïœæº¶æ¶²ãžãžã¯ãããšã¿ã³ã®ãšãŒãåãããæ²¹åã³ïœïœïœïœã®æº¶æ¶²ãã€ã³ã¯ãžã§ããããããšã«ãã調補ããããç²åŸååžããå³ïŒã«ç€ºãããé¡åŸ®é¡æ€æ»ç»åãå³ïŒïœã§äžããããã
ïŒïŒãã¯ãã³çäœãå«ããªã¯ã¿ã³âïŒâã€ã«ïŒïŒïŒïŒïŒâããªã»ãšãŒãã»ãã³ãŸã¢ãŒãã¯ãïŒïŒïœïŒšïœã®é床ã§ïŒïŒïŒïŒ ã®ïœïœïœæº¶æ¶²ãžãžã¯ãããšã¿ã³ã®ãšãŒãåãããæ²¹åã³ïœïœïœïœã®æº¶æ¶²ãã€ã³ã¯ãžã§ããããããšã«ãã調補ããããç²åŸååžããå³ïŒã«ç€ºãããé¡åŸ®é¡æ€æ»ç»åãå³ïŒïœã§äžããããã
Claims (9)
- ããªããŒç²åã®çç£ã®ããã®ããã€ã¹ã§ãã£ãŠãä¹³æ¿ãä¿æããããã®ç¬¬ïŒã®ãªã¶ãŒããšãåããæµäœãä¿æããããã®ç¬¬ïŒã®ãªã¶ãŒããšã第ïŒã®ãªã¶ãŒããæºããããŠãããšããåèšåããæµäœã«æµžããã液滎ãåèšåããæµäœãžçŽæ¥åŽåºå¯èœã«ããå°ãªããšãäžã€ã®ããºã«ãæã€åŽåºã¢ãžã¥ãŒã«ãšãåèšããºã«ãã第ïŒã®ãªã¶ãŒãå ã®åèšåããæµäœãžåŽåºããããšãã液滎ãåŸããé¢äžãžèœäžããåèšåŸããé¢ã«æ²¿ã£ãŠç§»åããããã«ã第ïŒã®ãªã¶ãŒããžãªã³ã¯ããåã¯äœçœ®ã¥ããããåœè©²åŸããé¢ãšãæãããããã€ã¹ã
- åèšåŸããé¢ã¯ã«ãŒãããŠãããè«æ±é ïŒã«èšèŒã®ããã€ã¹ã
- åèšåŸããé¢ã¯ãæ°Žå¹³ç·ã«å¯ŸããŠïŒïŒåºŠãšïŒïŒåºŠãšã®éã®è§åºŠã§çµãããè«æ±é ïŒã«èšèŒã®ããã€ã¹ã
- åèšããºã«ã¯ãïŒïŒÎŒïœããå°ããªçŽåŸãæã€ãè«æ±é ïŒã«èšèŒã®ããã€ã¹ã
- ïŒÎŒïœãšïŒïŒïŒÎŒïœãšã®éã®ç¯å²ã®ãµã€ãºãæã€ååæ£ãããã²ã«ããªããŒåŸ®ç²åã調補ããããã®æ¹æ³ã§ãã£ãŠãåèšåŸ®ç²åã¯çç©æŽ»æ§å€ãæããè«æ±é ïŒã«èšèŒã®ããã€ã¹ãå©çšãããåœè©²æ¹æ³ã¯ãïœïŒåèšçç©æŽ»æ§å€ãæããããªããŒã圢æãããããã²ã«ã®ä¹³æ¿ã調補ããã¹ããããšãïœïŒè£å©ã®å§åã䜿çšããæ¯åãä»äžããŠã氎溶åããæµäœã«æµžããããåèšããºã«ããã¹ãããïœïŒã®åèšä¹³æ¿ã®æ¶²æ»ŽãåŽåºããã¹ããããšãïœïŒæº¶åªã®é€å»ãšãåèšæ¶²æ»Žã®æ°Žã§ã®é£œåãšã確å®ã«ããæéã§ãåèšåããæµäœå ã«åèšæ¶²æ»Žã移åå¯èœã«ããããšã«ãããåèšæ¶²æ»ŽãèšããŸããŠç¡¬åããã¹ããããšãæããåœè©²ã¹ãããïœïŒã«ãããèšããŸããŠç¡¬åããã¹ãããã¯ãåèšåããæµäœå ã§ç²åãæ°Žå¹³ç·ã«å¯ŸããŠå°ãªããšãïŒïŒåºŠã®åŸæãæã€åŸããé¢ã移åã§ããããšã«ããå®æœããããæ¹æ³ã
- åèšããªããŒã¯ããããã²ã«ã»ããªããŒã§ãããè«æ±é ïŒã«èšèŒã®æ¹æ³ã
- åèšã¹ãããïŒïœïŒãã溶åªã®é€å»åã³æ°Žãšã®é£œåã確å®ã«ããæéã®éãåèšåããæµäœå ã§åèšç²åãåèšåŸããé¢äžã移åã§ããã¹ããããæãããè«æ±é ïŒåã¯ïŒã«èšèŒã®æ¹æ³ã
- åèšããºã«ããåŽåºããã液滎ãïŒãïŒïŒç§ã®éã®æéãåèšåŸããé¢ã«æ²¿ã£ãŠç§»åããããã«ãåèšåŸããé¢ã®é·ãåã³åŸæãæ§æããããè«æ±é ïŒä¹è³ïŒã®äœããäžé ã«èšèŒã®æ¹æ³ã
- ã¹ãããïŒïœïŒã®åŸãããæ··ããããšã«ããç²åãæŽã«å ããããè¿œå ã¹ãããïŒïœïŒãæãããè«æ±é ïŒä¹è³ïŒã®äœããäžé ã«èšèŒã®æ¹æ³ã
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07119102.7 | 2007-10-23 | ||
EP07119102 | 2007-10-23 | ||
PCT/IB2008/054300 WO2009053885A2 (en) | 2007-10-23 | 2008-10-20 | Methods for preparing polymer microparticles |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011506271A JP2011506271A (ja) | 2011-03-03 |
JP2011506271A5 true JP2011506271A5 (ja) | 2014-05-01 |
JP5733981B2 JP5733981B2 (ja) | 2015-06-10 |
Family
ID=40525268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010530598A Expired - Fee Related JP5733981B2 (ja) | 2007-10-23 | 2008-10-20 | ããªããŒåŸ®ç²åã調補ããæ¹æ³åã³ããã€ã¹ |
Country Status (5)
Country | Link |
---|---|
US (1) | US8313676B2 (ja) |
EP (1) | EP2205221A2 (ja) |
JP (1) | JP5733981B2 (ja) |
CN (1) | CN102215821B (ja) |
WO (1) | WO2009053885A2 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110293690A1 (en) * | 2010-05-27 | 2011-12-01 | Tyco Healthcare Group Lp | Biodegradable Polymer Encapsulated Microsphere Particulate Film and Method of Making Thereof |
GB201016433D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Apparatus and method for making solid beads |
GB201016436D0 (en) | 2010-09-30 | 2010-11-17 | Q Chip Ltd | Method of making solid beads |
CN102488619B (zh) * | 2011-12-05 | 2014-08-06 | äžæµ·äº€éå€§åŠ | è¿ç»ç产èŸå¡é£èœåŸ®ççè£ çœ®åæ§å¶åŸ®çéæŸé床çæ¹æ³ |
WO2014139168A1 (en) * | 2013-03-15 | 2014-09-18 | Tuo Jin | Preparation process of polymeric microspheres |
US20140294944A1 (en) | 2013-03-28 | 2014-10-02 | Kimberly-Clark Worldwide, Inc. | Microencapsulation of oxygen liberating reactants |
US10086353B2 (en) * | 2014-08-28 | 2018-10-02 | National Institute Of Advanced Industrial Science And Technology | Method and apparatus for producing dispersion |
US10471013B2 (en) | 2015-02-20 | 2019-11-12 | Blodvery Pharmatech, Ltd | Process for producing polymeric microspheres |
DE102015006727A1 (de) * | 2015-05-30 | 2016-12-01 | Rainer Pommersheim | Verfahren und technischer Prozess zur Herstellung von Mikro- und Nanopartikeln unterschiedlicher GröÃe |
GB2551944B (en) | 2015-12-18 | 2021-09-01 | Midatech Pharma Wales Ltd | Microparticle production process and apparatus |
US11045778B2 (en) * | 2016-08-05 | 2021-06-29 | Aptsol Srls | Dosage forms maturation device, machine and process for producing dosage forms with the device |
TWI643680B (zh) * | 2016-10-25 | 2018-12-11 | 財åæ³äººé屬工æ¥ç 究çŒå±äžå¿ | 埮ç²åŽé |
IT201600119699A1 (it) * | 2016-11-25 | 2018-05-25 | Eurotecnica Melamine Luxemburg Zweigniederlassung In Ittigen | Impianto e processo di produzione di urea solida in granuli |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4379682A (en) * | 1981-04-29 | 1983-04-12 | Ortho Diagnostics, Inc. | Reaction apparatus for the formation of microspheres or microcapsules |
US4375347A (en) * | 1981-04-29 | 1983-03-01 | Ortho Diagnostics, Inc. | Apparatus for promoting the formation of microparticles |
DE4338212C2 (de) * | 1993-11-10 | 1996-01-18 | Nukem Gmbh | Verfahren und Vorrichtung zur Herstellung von aus Kunststoff bestehenden Partikeln |
IT1274879B (it) * | 1994-08-03 | 1997-07-25 | Saitec Srl | Apparecchio e metodo per preparare forme farmaceutiche solide a rilascio controllato del principio attivo. |
EP1090928B1 (en) | 1999-09-30 | 2004-05-26 | Chienna B.V. | Polymers loaded with bioactive agents |
KR100902625B1 (ko) * | 2000-08-15 | 2009-06-15 | ë 볎ë ì€ëž ížë¬ì€í°ìŠ ì€ëž ë ì ëë²ìí° ì€ëž ìŒëŠ¬ë žìŽ | ë§ìŽí¬ë¡ì ì |
EP1404516A2 (en) | 2000-12-13 | 2004-04-07 | Purdue Research Foundation | Microencapsulation of drugs by solvent exchange |
US6767637B2 (en) | 2000-12-13 | 2004-07-27 | Purdue Research Foundation | Microencapsulation using ultrasonic atomizers |
US6669916B2 (en) | 2001-02-12 | 2003-12-30 | Praxair Technology, Inc. | Method and apparatus for purifying carbon dioxide feed streams |
WO2003079990A2 (en) | 2002-03-19 | 2003-10-02 | Purdue Research Foundation | Microencapsulation using ultrasonic atomizers |
US6998074B1 (en) | 2002-08-30 | 2006-02-14 | Microfab Technologies, Inc. | Method for forming polymer microspheres |
US20040166124A1 (en) | 2003-02-25 | 2004-08-26 | Dunfield John Stephen | Fluid-jet pens configured for making modulated release bioactive agents |
US7094045B2 (en) * | 2003-12-09 | 2006-08-22 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microencapsulation system and method |
US20080019904A1 (en) * | 2004-06-29 | 2008-01-24 | Koninklijke Philips Electronics, N.V. | System For Manufacturing Micro-Sheres |
EP1679065A1 (en) | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
-
2008
- 2008-10-20 JP JP2010530598A patent/JP5733981B2/ja not_active Expired - Fee Related
- 2008-10-20 WO PCT/IB2008/054300 patent/WO2009053885A2/en active Application Filing
- 2008-10-20 CN CN2008801126635A patent/CN102215821B/zh not_active Expired - Fee Related
- 2008-10-20 US US12/738,321 patent/US8313676B2/en not_active Expired - Fee Related
- 2008-10-20 EP EP08841414A patent/EP2205221A2/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5733981B2 (ja) | ããªããŒåŸ®ç²åã調補ããæ¹æ³åã³ããã€ã¹ | |
JP2011506271A5 (ja) | ||
US6767637B2 (en) | Microencapsulation using ultrasonic atomizers | |
Upadhyay et al. | Microbubble formulations: synthesis, stability, modeling and biomedical applications | |
JP5984903B2 (ja) | 埮ç²åã調補ããä¹³å€åºèª¿ããã»ã¹ãåã³ãããã»ã¹ã§å©çšãããã¯ãŒã¯ãããæ§é äœ | |
US6224794B1 (en) | Methods for microsphere production | |
US7309500B2 (en) | Microparticles | |
US6685957B1 (en) | Preparation of fibrous polymer implant containing bioactive agents using wet spinning technique | |
AU732891B2 (en) | Encapsulation method | |
US20080019904A1 (en) | System For Manufacturing Micro-Sheres | |
JPH11505250A (ja) | 補é èŠæš¡ã®åŸ®ç²åçææ¹æ³ | |
JPH09505308A (ja) | çç©åŠç掻æ§å€ãå«æããçå解æ§åŸ®ç²åã®è£œé | |
JP2001517615A (ja) | ããªããŒãåºå€ãšããå¶åŸ¡ãããæŸåºè£œå€ã®è£œé æ¹æ³ | |
US8846035B2 (en) | Methods for preparing polymer microparticles | |
WO2005061095A9 (ja) | 埮å°çäœã®è£œé æ¹æ³ããã³ãã®è£œé è£ çœ® | |
US10149826B2 (en) | Method of preparing microspheres | |
WO2001080835A1 (fr) | Procede de production de microspheres | |
EP1090928B1 (en) | Polymers loaded with bioactive agents | |
WO2003079990A2 (en) | Microencapsulation using ultrasonic atomizers | |
CN106074392A (zh) | äžç§ååºæµŽåªåæ³å¶å€çèåç©èœœè¯åŸ®çåå ¶æ¹æ³äžåºçš | |
Paradossi et al. | Soft condensed matter in pharmaceutical design | |
JP2002012670A (ja) | ãã€ã¯ãã¹ãã§ã¢ã®è£œæ³ | |
JP2020535224A (ja) | äºéãšãã«ã·ã§ã³æè¡ã«ãããã€ã¯ãç²åã調補ããæ¹æ³ |